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Summary 
Metamizole is an old analgesic agent. Its use is highly controversial due to its capacity to 
induce agranulocytosis, a rapid and severe fall of neutrophil granulocytes with risk of fatal 
outcome. Despite of this debate and withdrawal from the market in several countries, the 
use of metamizole increased in the last ten years in Switzerland as well as in Germany. The 
goal of this PhD-thesis project was therefore to improve our understanding of the clinical 
toxicity of metamizole. The work should contribute to a better understanding of the risk-
benefit profile and promote the safe use of metamizole. 
In a first approach, we descriptively analyzed worldwide pharmacovigilance data 
concerning adverse effects related to metamizole. The main objective was to characterize 
spontaneously reported cases of hematological adverse drug reactions associated with 
metamizole as suspected drug regarding appearance, course, and severity of the reactions. 
The worldwide case safety reports were selected from the WHO Global Individual Case 
Safety Report Database (VigibaseTM), and the national reports from the National 
Pharmacovigilance Database from Swissmedic. This allowed a comparison of reported 
hematological adverse drug reactions on a national and international level. A total of 1417 
international and 77 Swiss reports were analyzed. Around 52% of the international and 33% 
of the Swiss metamizole-associated hematological ADR occurred within  a  latency  time  of  ≤7  
days. More women were reported. The annual number of hematological reports and those 
with fatal outcomes increased over the last years parallel to metamizole sales figures. The 
minimal incidence rate of agranulocytosis was 0.46-1.63 cases per million person-days of use 
(2006-2012) estimated via sales figures and number of reports. Female sex, old age, 
pancytopenia, and co-medication with methotrexate were striking characteristics of the 7 
Swiss fatal cases. Early detection of myelotoxicity and avoidance of other myelotoxic 
substances like methotrexate (also at an immunosuppressive dose) are important measures 
for preventing fatalities. 
In a second study, we retrospectively performed a case-control study of metamizole 
associated leucopenias. We focused on the search of risk factors for the development of 
metamizole-induced white blood cell disorders. Fifty-seven cases and 139 controls were 
identified. Of the 57 cases, 32 were post-operative (post-OP) which were compared to age-, 
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sex- and ward-matched post-OP controls (n= 64). The remaining cases (n= 25) were 
compared to sex-matched, non-post-OP controls (n= 75). The number of patients with a 
positive allergy history was higher among post-OP cases than controls (p= 0.0015) as was the 
number with previous leucopenic episodes (p= 0.03). The prevalence of diagnosed hepatitis 
C infection was 7% among all cases compared to 1% among all controls (p= 0.01). The use of 
concomitant cytostatic agents (even at immunosuppressive doses) was significantly higher 
among non-post-OP cases than controls (p= 0.007), with a trend to this distribution among 
post-OP patients. We concluded that a history of allergies, leucopenic episodes, hepatitis C 
infection and concomitant cytostatic agents are possible risk factors leucopenia associated 
with metamizole use. 
The third project, a clinical study about the renal safety of metamizole, dealt with a 
possible advantage of metamizole. The aim of this study was to examine the effects of 
metamizole on renal function (inulin clearance and urinary excretion of sodium and of the 
prostacyclin metabolite 6-keto-PGF1α   in   healthy,   salt-depleted volunteers) in comparison 
with the non-specific COX-inhibitor naproxen. If it could be shown that metamizole does not 
have negative effects on renal function, its use in patients with impaired renal function who 
cannot be treated with NSAIDs would be supported. 
After single and repetitive dosing, neither metamizole nor naproxen had a significant 
effect on inulin clearance or sodium excretion. After repetitive dosing, there was a trend for 
decreased sodium excretion after naproxen but not after metamizole. Both metamizole and 
naproxen inhibited renal 6-keto-PGF1α  excretion  starting  2  hours  after  ingestion  and  lasting  
the entire dosing period during repetitive dosing, suggesting that metamizole inhibits renal 
prostaglandin synthesis similarly to naproxen. Therefore, renal excretion of 6-keto-PGF1α 
may not be the ideal marker to differentiate between the renal adverse effects of NSAIDs 
and metamizole. Nevertheless, in healthy, sodium-depleted subjects, metamizole had no 
significant effect on inulin clearance or renal sodium excretion, whereas there was a trend to 
a decreased sodium excretion after repetitive naproxen dosing. Further studies in more 
susceptible individuals have to be conducted in order to answer the question whether the 
effect of metamizole on renal function is different compared to NSAIDs. 
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Abbreviations 
4-AA   4-amino-antipyrine 
4-AAA   4-acetyl-amino-antipyrine 
4-FAA   4-formyl-amino-antipyrine 
4-MAA   4-methyl-amino-antipyrine 
ADR   adverse drug reaction 
AUC   area under the concentration–time curve 
Cmax   peak plasma concentration 
CNS   central nervous system 
COX   cyclooxygenase  
CYP   cytochrome P450 
G-CSF   granulocyte colony-stimulating factor 
GFR   glomerular filtration rate 
IAAAS   International Agranulocytosis and Aplastic Anemia Study 
IC50   half maximal inhibitory concentration 
LLOQ   lower limit of quantification 
NSAIDs  non-steroidal anti-inflammatory drugs 
PGE2   prostaglandin E2 
ROS   reactive oxygen species 
T1/2   half-life  
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1. Introduction 
1.1. Historical background: A long story 
Almost   100   years   of   metamizole’s   controversial   history   can   already be narrated. The 
story begins in Germany, where metamizole was first introduced by the company Hoechst in 
the 1920s [1]. But already in the early 1930s, metamizole was identified as a cause for severe 
blood dyscrasias, particularly agranulocytosis, together with other structural related 
pyrazolones including amidopyrine [2]. But several years have come and gone before the 
antipyretic analgesic has fallen increasingly into disgrace in the 1970s. This has led to 
withdrawal or banning in some countries (for example Australia 1965, Norway 1976, USA 
1977) [3]. The question how frequent metamizole induces agranulocytosis remained unclear 
but is essential for a proper evaluation of the risk benefit profile. In the 1980s, a population-
based case-control study, the International Agranulocytosis and Aplastic Anemia Study 
(IAAAS), tried to unveil this question for analgesic drug use [4]. The study analyzed 221 cases 
of agranulocytosis and 1425 hospital controls from centers in Israel, Spain, Germany, Italy, 
Hungary, Bulgaria and Sweden. The estimated excess risk for any exposure was 1.1 per 
million users within one week, but with striking local differences. The wide regional 
variability was linked with different utilization patterns of metamizole. Regions with a 
common use of metamizole (for example Israel and Hungary) showed lower risks, whereas 
regions in which metamizole is not commonly used showed higher rates (Germany and 
Spain). Subsequently, the hypothesis of a genetic predisposition was born [5]. But the study 
design and data analysis has been criticized substantially [6, 7]. Nevertheless, the low 
incidence found in the IAAAS somehow rehabilitated the reputation of metamizole to a 
certain degree. In Sweden for example, where the drug has been withdrawn in 1974 after a 
Swedish publication [8] with an estimated risk of 1 in 3000 patients, the results of the IAAAS 
led to reintroduction of metamizole in 1995, but it was withdrawn again in 1999 [9]. The ups 
and downs fit well with the sometimes quite emotional discussion regarding metamizole. 
Many publications were published dealing with the safety profile of this drug, not only in 
professional journals. Headings like   “Dipyrone   (Metamizole)   Use   in   the   United States: A 
Lethal Tango?”   or   “Dipyrone: A drug no one needs”   demonstrate   the   hard   front   of   the  
opponents [10, 11]. But this is only one side of the story. In other countries, metamizole 
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remained on the market, sometimes even as over the counter medication (for example 
Poland). In Switzerland, metamizole was subjected to prescription control in 1992 [3]. Today, 
the official indications in the Swiss product informations are severe pain or severe fever, 
which do not respond to other measures [12]. After some years of rather cautious use of 
metamizole, the Swiss sale figures started to rise again in the 2000s [13]. The same trend 
was observed in Germany [14]. The renaissance of the analgesic was paralleled by an 
increased awareness of the safety risks of treatment alternatives, namely non-steroidal anti-
inflammatory drugs (NSAIDs). Especially the cardio-vascular risk of NSAIDs has increasingly 
been recognized in addition to the well-known gastrointestinal and renal risk [15]. 
Metamizole seems to gain supporters again. 
 
1.2. Drug properties: What	  it’s	  like 
1.2.1. Mechanism of action 
Metamizole is one of the examples of an old drug with uncertain mechanism of action. 
Known are its analgesic, spasmolytic, and antipyretic effects [16]. The mechanisms of those 
actions have different origins.  
Spasmolytic effect 
The mode of action regarding the spasmolytic properties of metamizole has not been 
investigated in detail. The decrease of the excitability of peripheral smooth muscle is 
assumed to rise from a reduced increase of intracellular Ca2+ concentration by synthesis of 
inositol phosphate. The synthesis of inositol phosphate depends on phospholipase C which 
may be directly inhibited by metamizole or indirectly via inhibition of G protein-coupled 
receptors activating phospholipase C [17]. 
Antipyretic effect 
The antipyretic effect was first thought to be mediated by inhibition of prostaglandin E2 
(PGE2) synthesis via cyclooxygenase (COX)-inhibition, analogous to the antipyretic effects of 
NSAIDs [18, 19]. The inhibition of PGE2 production in the CNS which is responsible for the 
antipyretic effect, is thought to take place in the median preoptic nucleus located in the 
hypothalamus [20]. Inhibition of peripheral COX has actually been shown for metamizole in 
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several studies, but the reported half maximal inhibitory concentrations (IC50) for COX-1 
inhibition  shows  high  variability  ranging  from  2.6  μmol/L  to  >400  μmol/L  (in  comparison  IC50  
for COX-1 for ibuprofen 12-42  μmol/L,  and   for  naproxen  0.3-24  μmol/L) [21-24]. Similarly, 
the reported IC50 for COX-2 inhibition by metamizole show high variability ranging from 
4.7 μmol/L   to   >400   μmol/L [21, 22, 25]. Additionally, there is evidence for a PGE2 
independent mechanism contributing to the antipyretic effects [26, 27]. In 2014, Malvar and 
colleagues identified the metabolites 4-methylaminoantipyrine (4-MAA) and 4-
aminoantipyrine (4-AA) as the metabolites responsible for reduced Lipopolysaccharides 
(LPS)-induced fever and the reduced PGE2 increase in plasma, cerebrospinal fluid and 
hypothalamus. But only 4-MAA inhibited also PGE2-independet fever induced by Tsv (Tityus 
serrulatus venom). Apart of the antipyretic effects, 4-MAA shows hypothermic effects. An 
explanation for the mechanism of the hypothermic effect of 4-MAA is still missing [28].  
To sum up, the antipyretic action of metamizole is based on central effects, partially by 
COX-dependent effects via PGE2 inhibition, but also by PGE2-independent reactions by 
unknown mechanisms. In contrast to NSAIDs, metamizole has hypothermic effects at higher 
doses via unknown mechanisms. 
Analgesic effect 
Analogous to the antipyretic mechanism, the analgesic mechanism of metamizole is still a 
matter of ongoing investigations. As already mentioned, metamizole seems to inhibit COX 
with high and variable IC50 values, but possibly with a tendency to a preferred COX-2 
inhibition [21, 23]. Moreover, the inhibition of COX was described to be different from the 
direct interaction with the active center of the COX enzyme known from NSAIDs. Pierre and 
colleagues suggested an indirect COX-inhibition by sequestering radicals which COX needs 
for the catalytic activity and by the reduction of the oxidative state of COX [23]. Apart from 
the discussed COX-inhibition, other mechanisms are considered to explain the differences to 
NSAIDs. In 2012, Rogosch and colleagues identified two novel bioactive metabolites of 
dipyrone. The novel metabolites derived from metabolites already known, namely the 
arachidonoyl amides of 4-MAA and 4-AA. They were extracted from the CNS and were 
positively tested for cannabis receptor binding (CB1 and CB2) as well as COX inhibition [25]. 
Due to the association of metamizole with the endocannabinoid system, Crunfli and 
colleagues investigated in 2015 cannabinoid CB1 receptors mediated effects of dipyrone. 
They have examined mice treated with metamizole regarding known effects of 
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cannabinoids, including antinociceptive and cataleptic effects, hypolocomotion and 
hypothermia. Their results indicated involvement of the endocannabinoid system in the 
analgesic and cataleptic effect of metamizole and also of hypolocomotion, but not of 
hypothermic effects of metamizole. They hypothesized an indirect modulation of primarily 
CB1 receptors by providing additional arachidonic acid as substrate for endocannabinoid 
synthesis or other related molecules by inhibition of COX and fatty acid amide hydrolase 
(FAAH) [29]. An effect via endogenous opioids has been suggested before [30, 31]. But the 
complexity of suggested mechanisms of actions is not at all finished here. The peripheral 
antinociceptive effect was also associated with COX-independent activation of ATP-sensitive 
K+-channels [32]. The central analgesic effect was additionally linked with glutamatergic 
mechanisms, inhibition of neurokinin-1 (NK1) mediated responses, and inhibition of the 
protein kinase C-dependent pathway [33]. Lastly, also the descending serotonergic and 
noradrenergic system and appertaining spinal receptor subtypes (5-HT2a, 5-HT3, 5-HT7 -
serotonergic,   α1,   α2,   β-adrenergic receptors) seem to be involved in the antinociceptive 
effect of metamizole [34]. 
In summary, there is evidence for both, peripheral and central analgesic effects of 
metamizole. What strikes are the parallels of the proposed mechanisms with the suggested 
mechanisms of paracetamol. Paracetamol as well interacts with cannabinoid receptors [35]. 
Paracetamol also was shown to form an arachidonic acid-conjugated metabolite in the spinal 
cord and brain of mice by fatty acid amide hydrolase (FAAH) which acts as an agonist of the 
potent pain receptor TRPV1 (transient receptor potential cation channel subfamily V 
member 1) and inhibits purified COX-1 and COX-2 in vitro [36]. In the end, the revelation of 
the mechanisms of action of old drugs is of great interest for the development of new 
analgesics [37]. 
 
1.2.2. Pharmacokinetics 
Metamizole is a prodrug since it is immediately non-enzymatically hydrolyzed into the 
active metabolite 4-MAA in the gastrointestinal tract after oral administration but also 
directly after parenteral administration (Figure 1). Therefore, no parent substance appears in 
blood and urine. The bioavailability of this primary metabolite is high (85% for tablets, 89% 
for drops, 54% for suppositories, 87% for intramuscular injection) [16]. Peak plasma 
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concentrations (Cmax) of 4-MAA are reached within 1.4 to 2 hours [38]. No significant 
difference in drug exposure (area under the concentration–time curve (AUC) and Cmax) has 
been shown between fasting and non-fasting conditions [39].  
None of the major metabolites of metamizole showed a high plasma protein binding (4-
MAA 57.6%, 4-AA 47.9%, 4-FAA 17.8%, 4-AAA 14.2%) [40]. 4-MAA has a low volume of 
distribution (0.5 L/kg) without extensive tissue binding, matching to the hydrophilic 
properties of 4-MAA [16]. Actually, metamizole was developed as improved water-soluble 
form of the analgesic and antipyretic drug aminopyrine [41]. 
The quickly formed active metabolite 4-MAA is further demethylated, possibly in the 
liver, to the likewise active 4-AA. Cytochrome (CYP) P450 enzymes are suggested to be 
involved, but the specific CYPs have not yet been identified. There is indirect evidence for 
CYP 1A2 due to correlation between CYP 1A2 activity and aminopyrine metabolism, which is 
metabolized in the same way and to the same metabolites like metamizole [42, 43]. 
Alternatively, either directly from 4-MAA or via 4-AA, the inactive metabolite 4-formyl-
amino-antipyrine (4-FAA) is formed via oxidation, probably also mediated by CYPs. The last 
major metabolite rises from 4-AA which is acetylated to the inactive 4-acetyl-amino-
antipyrine (4-AAA). This step is performed by the hepatic polymorphic N-acetyl-transferase 
2, leading to marked varying levels of 4-AA (active) and 4-AAA (inactive) in slow and fast 
acetylators, respectively [44]. 4-MAA is the first metabolite reaching Cmax, but is also the 
first metabolite that falls below the detection limit. Both 4-AA and 4-FAA follow next to 
reach Cmax. The two metabolites are also the two main metabolites found in the urine [16]. 
Up to a dose of 1500 mg, the pharmacokinetics of 4-MAA is linear whereas higher doses 
show a deviation from linearity, but this was considered to be marginal for the usually 
applied dose range [38]. The four main metabolites mentioned above account together for 
approximately 70% of a dose [12]. Four minor additional metabolites have previously been 
described and new active metabolites in the CNS were discovered in 2012 [12, 25, 38]. The 
metabolites are primarily excreted in the urine, with a higher renal elimination after 
intravenous compared to oral application [45]. The half-life (T1/2) of 4-MAA after oral 
application of 1000 mg ranges between 2.5 and 3.5 hours [16]. Regarding the T1/2 of the 
other active metabolite 4-AA, it has to be distinguished between slow and fast metabolizers 
regarding N-acetyl-transferase 2. Slow metabolizers showed a longer T1/2 between 5.5 and 
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8.1 hours due to slower conversion into the N-acetyl-metabolite [16, 44]. Fast metabolizers 
have a T1/2 of about 3.8 hours [44]. Total body clearance for 4-MAA was found to be 
approximately 10 L/h with a renal clearance of about 0.24 L/h [16, 38].  
 
Figure 1 Metamizole metabolism 
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1.3. Hematological Safety: The big problem 
1.3.1. Definitions and incidence 
As a well-known fact, metamizole can induce agranulocytosis, a rapid and severe fall of 
neutrophil granulocytes with risk of fatal outcome. The definitions of blood cell disorders 
associated with metamizole are listed in the Table 1.  
Table 1 Definitions of blood cell disorders associated with metamizole [46, 47] 
 Definition 
Leucopenia Leucocyte count below 3.0 x 109/L 
Neutropenia Neutrophil granulocyte count below 1.5 x 109/L 
Severe Neutropenia Neutrophil granulocyte count below 0.5 x 109/L 
Agranulocytosis Neutrophil granulocyte count below 0.5 x 109/L with abrupt onset and 
clinical signs (fever, severe asthenia, buccopharynegeal and/or 
perineal ulcers) 
Pancytopenia Abnormal levels of all blood cell lines (anemia with neutropenia and 
thrombocytopenia) 
Aplastic Anemia Pancytopenia induced by a hypoplasia of the bone marrow 
 
Generally, the term agranulocytosis is understood as severe neutropenia with decreased 
neutrophil granulocytes below 0.5 x 109/L [48, 49]. The laboratory findings are accompanied 
with characteristic symptoms and signs, including an abrupt onset of fever, asthenia and 
buccopharynegeal or perineal ulcers [46]. Drug-induced agranulocytosis is a serious adverse 
event due to possible complications including severe sepsis associated with infections and 
septic shock. Although the mortality rate decreased over the last years, it is still in the range 
of 5% [50]. In about 70% of cases of drug-induced agranulocytosis an association with a drug 
can be found [51]. The first step in case of a potential drug induced agranulocytosis is 
therefore the withdrawal of all suspected drugs [49]. Other therapeutic options are 
intravenous application of broad-spectrum antibiotics in febrile patients [52] and 
granulocyte colony-stimulating factor (G-CSF) in patients with severe neutropenia and 
manifest or suspected infections [53-55]. But the evidence regarding the efficacy of G-CSF in 
patients with drug-induced agranulocytosis (outside of the oncology setting) is disputable 
[56]. The question about the frequency of this blood disorder is also controversial. As already 
mentioned in the historical background section (chapter 1.1), the published incidence rates 
vary markedly, as shown in Table 2. 
Table 2 Published incidence rates of metamizole-induced agranulocytosis (or aplastic anemia) 
Year Country / Study name Study design Incidence rate Ref. 
1979 Greece Retrospective epidemiological study 
(1 year, National Statistical Service of Greece) 
1:133’000 [57] 
1986 IAAAS/ Europe and Israel Population-based case-control study 
(221 agranulocytosis cases, 1425 hospital controls) 
1.1 cases per million users per week 
1:20’000 users/year 
[4] 
[58] 
1973 Sweden Pharmacovigilance data analysis 
Estimations, based on the reporting frequencies 
Calculated from reported numbers 
1:3000 users 
1:10’000 users 
[8] 
1981 Germany Calculation of German Bundesgesundheitsamt (BGA) 1:20’000 users/year [58] 
2002 Sweden Pharmacovigilance data analysis, sales data 1:1439 cases per prescription [59] 
2002 Poland Retrospective case study (5 years, approximately 15 million 
people), sales data 
0.2 cases per million person-days* [60] 
2004 Poland Prospective case study (1 year, approximately 15 million 
people), sales data 
0.25 cases per million person-days* 
(aplastic anemia) 
[61] 
2005 Spain Case-control surveillance study (78.73x106 person-years) 0.56 cases per million inhabitants per year [62] 
2010 Poland Prospective 12-month surveillance study 0.16 cases per million person-days* [63] 
2015 Germany Case-control surveillance study 0.96 cases per million per year* [14] 
IAAS International Agranulocytosis and Aplastic Anemia Study 
*potentially exposed patients (data from sale figures or statutory health insurance data divided per DDD (defined daily dose))
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1.3.2. Mechanisms of Toxicity 
Immune-mediated toxicity 
Another unsolved question is the mechanism of metamizole-induced agranulocytosis. 
The mechanism is idiosyncratic, since the adverse reaction develops with therapeutic doses 
and is a rare event. Idiosyncratic toxicities can be immune-mediated or non-immune-
mediated (metabolic) [64]. A schematic overview of possible mechanisms is shown in Figure 
2. Arguments for an immune-mediated toxicity are described cases with a toxicity following
only one dose, the lack of a distinct dose-dependency, or aggravated reactions after a 
rechallenge. In case of immunological drug induced agranulocytosis, the drug, or more likely 
a reactive metabolite, may act as hapten (a hapten is a small molecule that can provoke an 
immune response only when attached to a large carrier) that binds to the neutrophil 
membrane glycoproteins. Due to this binding, the immune system identifies the changed 
structure of the membrane no longer as endogenous structure and antibodies or T-cells 
directed against the altered structure of the membrane are produced. This mechanism has 
been shown for the thyreostatic drug propylthiouracil, the antimalarial drug amodiaquin, 
and the antiarrhythmic drug flecainide [65-69]. The production of autoantibodies against 
neutrophils, without binding of the drug or a metabolite to the neutrophil plasma 
membrane, has also been suggested [65]. For aminopyrine, which is closely structurally 
related to metamizole and is converted to the same metabolites, drug-dependent antibodies 
that lead to destruction of mature neutrophils have been demonstrated in vitro and in vivo 
[70, 71]. In transfusion experiments, Swiss investigators administered two subjects 
aminopyrine (rumor has it that it was a self-experiment) and injected 300 mL blood from a 
patient with aminopyrine-induced agranulocytosis. They were able to induce in both 
subjects a distinct fall of neutrophils (from 5000/mm3 to 800/ mm3 and from 8400/mm3 to 
1700/mm3 within 40 min). The transfusion of blood of a healthy person in the recipients 
showed no decrease of leucocytes as well as orally administered aminopyrine one week 
after the transfusion [71]. Thus, drug-dependent antibodies are able to destroy mature 
neutrophils in the periphery. But typically, the bone marrow of patients with metamizole-
associated agranulocytosis shows either too few cells or a halt in the maturation of 
granulopoietic precursors (maturation arrest). Due to the invasive character of a bone-
marrow puncture, an examination is often omitted. But although the bone marrow of a 
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metamizole-induced agranulocytosis is not uniformly described, the maturation arrest on 
the level of myelocytes or promyelocytes is considered as typical finding for a toxic drug-
induced bone marrow damage [72, 73]. Precursors can therefore be affected as well [48, 
74]. Interestingly, the lack of granulocyte precursors concerns cells back to the promyelocyte 
stage, which is the stage when neutrophil precursors start to synthesize myeloperoxidase 
[75]. This suggests a role of reactive oxygen species (ROS) and the production of reactive 
metabolites as a mechanism of drug-induced agranulocytosis [76, 77]. 
Figure 2 Schematic overview of possible mechanisms of the hematologic toxicity 
Non-immune-mediated (metabolic) toxicity 
The toxicity associated with ROS formation is traditionally classified as non-immune-
mediated or metabolic toxicity. Hints for metabolic toxicity include the fact that all three 
blood cell lines can be affected and the lack of accompanying immunological features in 
patients with metamizole-induced agranulocytosis (for example eosinophilia, rash or fever). 
In case of drug-induced agranulocytosis, metabolic toxicity is usually understood as a 
damage of the myeloid progenitor cells in the bone marrow without direct involvement of 
immunological pathways. Either the drug itself or a reactive metabolite damages the cells. 
Regarding myelotoxicity, the cytotoxic effect of anticancer drugs is a good example of 
neutropenia caused by a dose-dependent or intrinsic mechanism. Non-chemotherapeutic 
drug-induced agranulocytosis is an idiosyncratic drug reaction which occurs at a therapeutic 
dosage and is therefore supposed to be unpredictable [78]. Regarding metamizole, there are 
some studies indicating dose-dependent toxicity to promyelotic cells. In vitro experiments 
with HL-60 promyelocytes showed that metamizole and 4-MAA induce apoptosis, but only at 
supratherapeutic concentrations (concentrations above 100 µM, therapeutic levels reach 
approximately 50 µM) [79].  
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Teamwork between immune-mediated and non-immune-mediated toxicity 
Meanwhile, the distinction between immune-mediated and metabolic mechanisms is 
increasingly questioned due to new insights into the regulation of myelopoesis and 
neutrophil maturation as well as new concepts of immunological pathways, including the 
pharmacological interaction (PI) hypothesis and the danger hypothesis [64, 80, 81]. 
Especially the danger hypothesis may help to understand the question, how a reactive 
metabolite can initiate an immune response and therefore enable the combination of 
metabolic and immune-mediated toxicity [75].  
According to the already introduced current idea, generation of ROS could lead to hapten 
formation. Via NADPH oxidase and myeloperoxidase, neutrophils generate ROS which are 
needed to oxidize or kill drugs or pathogens. Apart of neutrophils and myeloid progenitor 
cells starting at the promyelocyte stage, significant quantities of myeloperoxidase are also 
present in monocytes and macrophages [82]. One of the formed ROS is hypochlorus acid 
that is considered to be a major factor for oxidizing drugs into reactive metabolites. Such 
reactive metabolite formed can bind covalently to cellular molecules, which creates a 
complex that may serve as a hapten and thereby favoring T-cell mediated immune reactions 
[64]. The formation of a very reactive metabolite by hypochlorus acid has been 
demonstrarted for aminopyrine [83]. Another possibility of how a reactive metabolite can 
induce or modulate immune reactions is provided by the danger hypothesis. Matzinger and 
colleagues described 1994 the idea that organisms can differentiate between harmless and 
dangerous, similar to the immunological paradigm of self and non-self (as implied by the 
hapten hypothesis) [81]. The two hypotheses are not mutually exclusive. According to the 
hapten hypothesis, the complex of reactive metabolite bound to a protein (hapten) is taken 
up and processed by antigen-presenting cells and finally presented to helper T cells, which 
recognize it as non-self (signal one). According to the danger hypothesis, the drug or reactive 
metabolite can cause cell damage, leading to a release of “danger signals” that upregulates 
costimulatory factors for the antigen-presenting cell (signal two). Both signals, signal one 
and two, are needed for the initiation of a strong T-cell proliferation [75]. In contrast to the 
classical immune approach, not cells of the immune system are the main stimulus for the 
initiation of an immune response, but endogenous signals from damaged tissues [81]. 
Without these second signals, there would be immune tolerance [84]. The question, which 
kind of danger signals are formed, is unclear. Preliminary data suggest that activation of 
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inflammasomes could be one mechanism, with production of inflammatory cytokines (IL-1β  
and IL-18) which may act as danger signals [85]. Additional factors associated with cell 
damage including infections, may increase the risk for such reactions [86]. 
To sum up, reactive metabolites seem to play a crucial role in metamizole-induced 
agranulocytosis via direct (metabolic) toxicity and/or via stimulating immune-mediated 
destruction of granulocyte precursors in the bone marrow [64]. 
1.3.3. Risk factors and genetic susceptibilities 
Since metamizole-induced agranulocytosis is considered to be idiosyncratic and is 
therefore not dose-dependent, investigations trying to find risk factors for the development 
of this disorder were performed. Female sex has been suggested in several studies due to a 
higher proportion of affected women [59, 60, 87]. Likewise, drug-induced agranulocytosis 
has been associated with higher age [88, 89]. Both risk factors where assumed to be 
eventually exposure-related, but clarifying data was missing. An increased risk with 
increasing duration of treatment has been discussed as well [14, 62]. But in the systematic 
review of Andersohn and colleagues about non-chemotherapeutic drug-induced 
agranulocytosis, metamizole showed a median drug exposure of only two days, emphasizing 
the existing risk even in short-time therapies [49]. A higher dose, in addition to longer 
therapy durations, was also supposed to be a possible risk factor [62]. This hypothesis is not 
supported by the fact that metamizole-induced agranulocytosis is not associated with cases 
of overdoses. A review of cases of metamizole overdoses found mainly mild gastrointestinal 
complications but not bone marrow damage [90]. Moreover, there are case reports of 
kidney toxicity without hematotoxicity after metamizole overdose [91, 92].  
Concomitant drugs, especially such with a known risk for agranulocytosis, have also been 
investigated as possible risk factors [59, 62], but no clear implications were reported. 
Regarding underlying diseases, especially allergies and viral infections were considered as 
potential risk factors [59, 93, 94].  
The investigation of a possible genetic predisposition is still in its infancy. In 1996, Vlahov 
and colleagues published a paper about genetic risk factors of metamizole-induced 
agranulocytosis [5]. They examined five patients with metamizole-induced agranulocytosis 
and four patients with agranulocytosis independent of metamizole and compared them to a 
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reference group of 180 healthy subjects. In the collective of the nine agranulocytosis 
patients, more were carriers of the human lymphocyte antigen 24 (HLA24) antigen and less 
of the DQA1*0501 allele compared to the controls (11% versus 57%). Regarding the 
metamizole-associated agranulocytosis patients, the HLA24-B7 haplotype was found with a 
higher frequency than in the metamizole-independent cases and controls. Additionally, all 
five patients with metamizole-associated agranulocytosis were found to have a HLA-DQwl 
antigen and in four of five also a HLA2 antigen, while in the control group only 56% were 
carriers of these genes. The number of cases in this study is very small, but the study has 
shown relevant differences regarding human lymphocyte antigen HLA allele frequencies. In 
2015, a new study about the genetic determinants of metamizole metabolism which modify 
the risk of developing anaphylaxis has been published [95]. Their results support the 
hypothesis of genetically determined metabolic variability as a risk factor for developing 
anaphylaxis. Slow acetylators showed an increased risk of developing selective 
hypersensitivity, especially anaphylaxis. But there are no hints for a higher risk for 
agranulocytosis in patients with slow acetylation [5]. In summary, little is known about the 
genetic predisposition, leaving a big potential for further investigations.  
1.4.  Renal Safety: A possible advantage 
Apart from the discussion about the risks of metamizole, benefits of the substance 
quickly get forgotten. One benefit of metamizole compared to NSAIDs is its supposed better 
renal tolerability. The available data basis for this hypothesis, however, is poor. It is still not 
entirely clear, whether metamizole is a valuable alternative to NSAIDs in patients with low 
intravascular pressure (stimulated renin-angiotensin-aldosterone system), where 
prostaglandins are crucial for the maintenance of renal perfusion. This concerns patients 
with diseases such as heart failure, liver cirrhosis with ascites, chronic renal insufficiency or 
nephrotic syndrome [96]. Of course, this is related to the unclear mechanism of action. The 
question, whether metamizole inhibits renal prostaglandin synthesis has to be answered as 
well as the question, whether metamizole shows an acute effect on renal function in 
sensitive patients. Regarding renal complications, mainly case reports, case series and 
reviews about acute kidney injury (AKI) or acute interstitial nephritis (AIN) are described in 
the literature [91, 97, 98]. The absolute number of cases reported, however, is small. Berruti 
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et al. [98] described the differences between the clinical presentations of acute interstitial 
nephritis after metamizole intake compared with NSAIDs. The shortened time course 
between the metamizole administration and the clinical presentation (24 hours to a few 
days for metamizole versus several months up to 1 year for NSAIDs), as well as the lack of 
significant proteinuria in the metamizole cases compared with a NSAID-induced acute 
interstitial nephritis have been discussed. Finally, the accuracy of the diagnosis of the 
metamizole-induced acute interstitial nephritis can be questioned. 
Overall, clinical experience suggests better renal tolerability of metamizole possibly due 
to less potent renal COX-inhibition compared to classical NSAIDs. If this could be confirmed, 
metamizole would be a valuable alternative for treatment of painful conditions in patients 
with impaired renal function.  
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2. Aims of the thesis: Remaining questions
As apparent from the introduction, many questions remain around the old substance 
metamizole. Considering the increasing use of metamizole, the demand for more 
information about metamizole has gained relevance. The goal of this PhD-thesis project was 
to improve our understanding of the clinical toxicity of metamizole. The planned work 
should contribute to a better understanding of the risk-benefit profile and promote the safe 
use of metamizole. To reach this goal, the PhD thesis project has been divided into the 
following three subprojects: 
 Descriptive analysis of pharmacovigilance data concerning adverse effects related
to metamizole
 Retrospective case control-study of metamizole-associated leucopenia
 Clinical study investigating the renal safety of metamizole in salt-depleted healthy
volunteers
The main objective of the pharmacovigilance analysis was to characterize spontaneously 
reported cases of hematological adverse drug reactions with metamizole as suspected drug 
regarding appearance, course, and severity of the reactions. The case safety reports were 
either selected from the WHO Global Individual Case Safety Report Database (VigibaseTM) or 
from the National Pharmacovigilance Database Swissmedic. This investigation allowed a 
comparison of reported hematological adverse drug reactions on a national and 
international level. 
After the characterization of pharmacovigilance data cases, the retrospective case-
control study focused on the search of risk factors for the development of metamizole-
induced white blood cell disorders. In addition of the detailed characterization of patients 
with metamizole-induced agranuloyctosis managed at the University Hospital Basel, the 
comparison with a control group should allow more valid identification of risk factors.  
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The clinical study about the renal safety of metamizole, however, dealt with a possible 
advantage of metamizole. The aim of this study was to examine the effects of metamizole on 
renal function in comparison with the non-specific COX-inhibitor naproxen. If it could be 
shown that metamizole does not have negative effects on renal function, it would support 
the use of metamizole in patients with impaired renal function that cannot be treated with 
NSAIDs. 
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3. Results
Before immersing into the three main projects, let’s	  start	  with	  a	  case.	  The	  case	  shows	  
impressively the brisance of the topic and makes it easy to understand that a once 
experienced negative event constraints to legitimate caution. 
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Fatale Agranulozytose nach 
 Metamizol- Reexposition
Fatal Agranulocytosis after Re-Exposure to Metamizole
Anamnese und Befunde
Ein 63-jähriger Patient wurde Mitte 
Mai 2014 notfallmässig aus der Alters-
siedlung aufgrund seit dem Vorabend 
bestehenden Fiebers und respiratori-
scher Verschlechterung hospitalisiert. 
Als Grunderkrankungen lagen ein be-
ginnendes dementielles Syndrom bei 
chronischem Alkoholkonsum, eine Kar-
diopathie (am ehesten äthylotoxisch) 
und ein Typ-2-Diabetes mellitus vor. 
Aufgrund von Schmerzen bei bekannter 
Polyneuropathie war zehn Tage zuvor 
eine Metamizol-Therapie mit Novalgin® 
500 mg dreimal täglich peroral gestartet 
worden. Die weitere Eintrittsmedikation 
bestand aus Pantoprazol 40 mg/d, To-
rasemid 10 mg/d, Levocetirizin 5 mg/d, 
Atenolol 10 mg/d, Escitalopram 10 mg/d, 
Magnesium 5 mmol/d. Auf der Notfall-
station zeigte sich der Patient febril bis 
38,7°C, kaltschweissig, hypoton (BD 
109/80 mmHg), tachykard (Herzfre-
quenz 120/min) und dyspnoisch mit 
einem Sauerstoffbedarf von 15 l/min. 
Klinisch fielen diffuse Rasselgeräusche 
über allen Lungenfeldern auf bei sonst 
unauffälligem Status. Im Notfalllabor 
imponierte eine Agranulozytose (Neu-
trophile 0,001×109/l [Normbereich 
 1,3–6,7×109/l]), Leukozyten 0,19×109/l 
[3,5–10,0], erhöhte Entzündungswerte 
( CRP 280 mg/l [<10 mg/l], pCT 12 ng/ml 
[<0,1 ng/ml]) sowie ein erhöhtes Krea-
tinin (125 µmol/l [49–79 µmol/l]). Die 
Thrombozytenzahl war zudem leicht 
reduziert (125×109/l [150–450]), das 
 Hämoglobin jedoch im Normbereich.
Bei zunehmender Verschlechterung und 
klinischem Bild eines schweren septi-
schen Schocks erfolgte die Verlegung 
auf die medizinische Intensivstation, wo 
der Patient aufgrund respiratorischer 
Erschöpfung intubiert werden muss-
te. Da unter Volumensubstitution und 
Noradrenalingabe der Kreislauf nicht 
ausreichend stabilisiert werden konnte, 
erfolgte die zusätzliche Gabe von Ad-
renalin. Bei echokardiographischem 
Nachweis einer schwer eingeschränkten 
Pumpfunktion bei bekannter äthyltoxi-
scher Kardiopathie begannen wir zudem 
mit Dobutamin. Bei zunächst unklarem 
Infektfokus erfolgte eine Breitspektrum-
antibiotika-Therapie mit Meropenem. 
Des Weiteren erhielt der Patient Infekt-
prophylaxen mit Aciclovir, Fluconazol 
und Trimethoprim/Sulfamethoxazol. 
Computertomografisch zeigten sich bi-
laterale Infiltrate. Bei vorbestehenden 
perinealen Fisteln erfolgte eine prophy-
laktische Seton-Drainageneinlage, bild-
morphologisch ergab sich jedoch kein 
Hinweis für eine Abszessformation.
Ungefähr 18 Monate zuvor hatte der 
Patient nach einer Halswirbelkörper-
fraktur bereits auf Metamizol mit einer 
Agranulozytose (ohne Beteiligung an-
derer Zelllinien) reagiert, die sich nach 
Absetzen des Medikaments und Be-
handlung mit Granulozyten-Kolonien 
stimulierenden Faktoren (G-CSF) er-
holte. Die Neutropenie präsentierte sich 
 damals in einer Routine-Blutbildkon-
trolle zwölf Tage nach Metamizol-Be-
ginn und lag bei 1,123×109/l [Normbe-
reich 1,3–6,7×109/l] und fiel auf einen 
Nadir von 0,021×109/l sieben Tage spä-
ter. Unter der damaligen Neutropenie 
hatte er perianale Fisteln mit Abszess-
bildung entwickelt, die chirurgisch an-
gegangen werden mussten. Als andere 
mögliche medikamentöse Auslöser der 
damaligen Agranulozytose kamen auch 
Quetiapin und Piperacillin/Tazobactam 
infrage.
Differenzialdiagnostische 
Gedanken
Eine wiederholte Agranulozytose nach 
Metamizol-Reexposition, wie in diesem 
Fall, machte eine Metamizol-induzierte 
Agranulozytose zur wahrscheinlichsten 
Diagnose. Gemäss WHO-Kausalitäts-
kriterien für unerwünschte Arzneimit-
telwirkungen (UAW) war Metamizol als 
sicherer Auslöser der Agranulozytose zu 
betrachten [1].
Weitere Abklärungsschritte 
und Verlauf
Im Verlauf konnten als Erreger Strep-
tokokken der Gruppe A in den Blut-
Im Artikel verwendete Abkürzungen: 
BD Blutdruck
 CRP  C-reaktives Protein
G- CSF  Granulozyten-Kolonien 
 stimulierender Faktor
pCT Procalcitonin
 UAW  Unerwünschte Arzneimittel-
wirkung
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kulturen wie auch im Trachealsekret 
nachgewiesen werden und die antibio-
tische Therapie resistenzgerecht auf 
Clindamycin und Ceftriaxon umgestellt 
werden. Unter Behandlung mit G-CSF 
kam es nur zu einer geringfügigen Sti-
mulation der Proliferation der Granu-
lozyten. Trotz Ausbau der Vasoaktiva, 
zusätzlicher Hydrocortisongabe und 
Applikation von Immunglobulinen ver-
lief die Sepsis weiter fulminant. Es kam 
zu ausgeprägten Perfusionsstörungen 
der Extremitäten sowie anurischem 
Nierenversagen. Nach Stopp der sedie-
renden Medikamente zeigte sich der 
Patient weiterhin komatös, sodass auch 
von einer zerebralen Beeinträchtigung 
durch die Sepsis ausgegangen worden 
ist. Es wurden mehrere Gespräche mit 
den Angehörigen geführt und man 
entschied sich, gemäss mutmasslichem 
Patientenwillen und infauster Progno-
se, auf eine Fortführung der lebensver-
längernden Massnahmen zu verzichten. 
Der Patient verstarb am fünften Hospi-
talisationstag.
Beide Metamizol-induzierten Agra-
nulozytose-Episoden wurden gemäss 
Bundesgesetz innerhalb von 15 Tagen 
als schwerwiegende unerwünschte Arz-
neimittelwirkungen in anonymer Form 
beim Schweizerischen Heilmittelinstitut 
(Swissmedic) gemeldet.
Diagnose
Fataler septischer Schock mit Streptococ-
cus pyogenes und Multiorganversagen bei 
Metamizol-induzierter Agranulozytose
Kommentar
Im vorliegenden Fall kam es nach er-
neuter Metamizol-Exposition zu einer 
schweren Agranulozytose mit fatalen 
Konsequenzen. Der Fall unterstreicht, 
wie ernst eine medikamentös induzier-
te Agranulozytose in der Vorgeschichte 
zu nehmen ist. Trotz Vermerk «Dauer-
hafter Verzicht auf Novalgin®» im Aus-
trittsbericht kam es zu einer erneuten 
Exposition. Ein Grund hierfür könnte 
die Tatsache sein, dass drei verdächtige 
Medikamente als Auslöser bei der ersten 
Episode infrage kamen. Eine Metami-
zol-Rechallenge bei Notwendigkeit einer 
Schmerzlinderung bei einem Patienten 
mit erhöhtem Alkoholkonsum wurde 
vielleicht deswegen trotzdem als vertret-
bar eingestuft. Zudem könnte das de-
menzielle Syndrom einen ungünstigen 
Einfluss auf die Mitteilungsverantwor-
tung des Patienten ausgeübt haben oder 
gar seine Erinnerung an die vorausge-
gangene Agranulozytose verunmöglicht 
haben. Weiter sind UAW, die im Spital 
auftreten, für Patienten oft weniger ein-
schneidend und somit auch weniger 
präsent. Eine Art «Kontraindizierte Me-
dikamente-Pass» (analog zu einem All-
ergie-Pass), der immer auf sich getragen 
werden muss, könnte als Massnahme 
zur Verhinderung solcher Ereignisse er-
wogen werden. Dieser Fall unterstreicht 
die Wichtigkeit einer lückenlosen Kom-
munikation der verschiedenen Mitspie-
ler im Gesundheitswesen.
Mechanismus
Der Mechanismus der Metamizol-in-
duzierten Agranulozytose ist leider ak-
tuell nur unzureichend aufgeklärt [2]. 
Metamizol wird jedoch häufiger einge-
setzt [3], weshalb ein Anstieg in der Ge-
samtfallzahl von Metamizol-induzierten 
Agranulozytosen in der Schweiz und in 
Deutschland zu erwarten ist.
Zwei pathogenetische Ursachen werden 
vermutet [2]. Es gibt Hinweise für eine 
immunologische Pathogenese, aber auch 
für eine direkte toxische Schädigung der 
Vorläuferzellen im Knochenmark. Bei 
der immunvermittelten Agranulozytose 
handelt es sich um eine allergisch beding-
te Reaktion, bei der das Pharmakon oder 
einer seiner Metaboliten als Hapten oder 
Prohapten fungiert und eine humorale 
oder zelluläre Immunreaktion auslöst 
[4]. Gemäss dem p-i(pharmakologische 
Interaktion)-Konzept kann eine Immun-
antwort auch über direkte Interaktion 
von Arzneistoffen oder Metaboliten mit 
dem  T-Zell-Rezeptor erfolgen [5].
Bei dem direkt knochenmarktoxischen 
Mechanismus handelt es sich in der Re-
gel um einen schleichenden toxischen 
Prozess. Dieser ist meist zeit- wie auch 
dosisabhängig. Für eine Zeitabhängig-
keit spricht die Tatsache, dass eine Agra-
nulozytose nicht in Fällen von akuter 
Toxizität (z.B. in Rahmen einer einma-
ligen Überdosierung) beobachtet wird 
[6]. Nach längerer Medikamentenein-
nahme kann es zu einer toxischen Schä-
digung der Vorläuferzellen im Knochen-
mark kommen [7]. Metaboliten können 
an Kernmaterial oder an zytoplasma-
tische Proteine binden und dadurch 
eine direkte Toxizität an den Myeloid-
Vorläuferzellen im Blut oder Knochen-
mark ausüben [2]. Es können auch an-
dere Blutzelllinien betroffen sein. Immer 
wieder werden Fälle von Metamizol-
induzierten Bizytopenien (wie in diesem 
Fall) oder Panzytopenien berichtet [8].
Epidemiologie
Metamizol gehört zu jenen Medikamen-
ten, die am häufigsten mit Agranulozy-
tosen assoziiert sind [9,10]. Eine Studie 
aus Spanien errechnete eine Odds Ratio, 
eine Agranulozytose unter Metamizol 
zu entwickeln, von 26 im Vergleich zu 
nicht-exponierten Kontrollen [10]. Die 
Inzidenz der Metamizol-induzierten 
Agranulozytose wird unterschiedlich 
berichtet und eingeschätzt und variiert 
zwischen 1:1439 Verschreibungen bis zu 
1:1 Mio. Anwender pro Woche [11]. Eine 
geografische und/oder genetische Prä-
disposition scheint vorzuliegen [12]. Die 
Mortalität lag in früheren Jahren bei bis 
zu 29%, wird aber heute zwischen 5 und 
7% geschätzt [11]. Eine Bi- oder Panzy-
topenie ist mit einer erhöhten Mortalität 
assoziiert [8]. Dabei muss zwischen den 
beiden Krankheitsbildern Agranulozy-
tose und aplastische Anämie unterschie-
den werden. Eine Agranulozytose, die 
ausschliesslich die Neutrophilen betrifft, 
ist meist reversibel nach Absetzen der 
Verursacher, während eine aplastische 
Anämie, die zu einer Panzytopenie mit 
hypozellulärem Knochenmark führt, 
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ohne entsprechende Behandlung meist 
nicht reversibel ist. Aufgrund der geo-
graphischen Variation in der Inzidenz 
und des immer noch erhöhten Risikos, 
an einer Agranulozytose zu sterben, ist 
Metamizol in mehreren Ländern nicht 
zugelassen, wie z.B. den  USA, Grossbri-
tannien und Schweden [8,13].
Es liegen in der Literatur unseres Wis-
sens bisher nur zwei Fälle zu einer wie-
derholten Agranulozytose nach einer 
Reexposition mit Metamizol vor. In bei-
den Fällen trat eine erneute Neutropen-
ie auf [12]. Zwischen 1969 und Januar 
2013 ist weltweit 920 Mal eine mit Meta-
mizol assoziierte Agranulozytose bei der 
WHO gemeldet worden (Vigisearch-Su-
che) [14]. Bis zur Datenzusammenschau 
(7.7.2014) hat sich die weltweit gemelde-
te Anzahl Metamizol-assoziierter Agra-
nulozytosen auf 1042 erhöht, wovon 68 
Fälle aus der Schweiz stammen. Unter 
den Fällen, die zwischen 1969–2013 ge-
meldet wurden, entwickelte sich in 23 
Fällen die Agranulozytose nach einer 
Reexposition [14]. In zwei Reexpositi-
onsfällen wurde eine Panzytopenie be-
richtet und in einem Fall eine hypozellu-
läre Knochenmarkhistologie. Insgesamt 
sind drei Patienten gestorben, zwei erlit-
ten anhaltende Beschwerden und in fünf 
Fällen war der Outcome nicht bekannt. 
Die Mortalität nach einer Reexposition 
scheint daher in etwa zwischen 13 und 
17% zu liegen.
Management
Es liegen keine formalen Leitlinien zur 
Behandlung einer Metamizol-induzier-
ten Agranulozytose vor. Eine Agranulo-
zytose bleibt asymptomatisch bis zum 
Auftreten einer infektiösen Kompli-
kation. Gemäss Fachinformation wird 
keine routinemässige Überwachung des 
Blutbildes unter Metamizol-Therapie 
empfohlen (im Gegensatz zu Clozapin). 
Eine gute Übersicht zur Behandlung 
Medikament-induzierter Agranulozy-
tosen ist im Uptodate® zu finden [15]. 
Als erste Massnahme sollten in jedem 
Fall Metamizol und, wenn vorhan-
den, andere verdächtige Medikamen-
te abgesetzt werden. Durch Absetzen 
der verdächtigen Medikamente ist die 
Agranulozytose meist reversibel. In der 
Regel erholt sich die Neutrophilenzahl 
innerhalb von ein bis drei Wochen ohne 
G-CSF-Behandlung [15]. Zudem sollte 
eine antibiotische Therapie sowie eine 
G- CSF-Behandlung in Betracht gezo-
gen werden. Allergologische Abklärun-
gen nach Abklingen der Reaktion sind 
zurzeit nicht in der Routineklinik etab-
liert. Allerdings laufen hierzu klinische 
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Key messages
 ! Die Metamizol-induzierte Agranulozytose ist eine schwerwiegende uner-
wünschte Arzneimittelwirkung.
 ! Bei hospitalisierten Patienten, die einen Neutrophilen-Abfall oder Agranu-
lozytose unter Metamizol entwickeln, muss das Metamizol sofort abgesetzt 
werden. Prophylaktische Antibiotika bei fehlendem Fieber oder Infektzeichen 
sind nicht routinemässig indiziert. Sobald jedoch Infektzeichen auftreten, 
sollte unverzüglich eine Breitspektrumantibiotika-Therapie begonnen wer-
den, ohne die Abklärungen abzuwarten.
 ! Ambulante Patienten müssen instruiert werden, Metamizol bei Fieber und/
oder Halsschmerzen abzusetzen und sich notfallmässig beim Arzt vorzustel-
len.
 ! Eine Reexposition nach stattgefundener Agranulozytose, bei der Metamizol 
verdächtigt war, muss vermieden werden, da ein schwerwiegender Verlauf 
wahrscheinlich ist.
Zusammenfassung
Wir stellen den Fall eines 63-jährigen 
Mannes vor, der einen schweren sep-
tischen Schock mit letalem Ausgang 
auf Basis einer Agranulozytose ent-
wickelte. Aufgrund des zeitlichen Zu-
sammenhangs, der Verbesserung nach 
Dechallenge in der Vorgeschichte und 
aktuellem Rechallenge ist der Kau-
salzusammenhang für eine erneute 
Metamizol-induzierte Agranulozytose 
sicher. Wir diskutieren die Wichtig-
keit, Patienten mit einer verdächtigten 
 Metamizol-induzierten Agranulozy-
tose nicht erneut zu exponieren und 
Patienten sowie behandelnde Ärzte lü-
ckenlos zu informieren.
Schlüsselwörter: Agranulozytose – 
Metamizol – Septischer Schock
Abstract
We present the case of a 63 year old 
man who died of severe septic shock 
in the setting of agranulocytosis in-
duced by dipyrone (metamizole). 
The patient had previously developed 
agranulocytosis after dipyrone expo-
sure 18 months prior to this. The case 
illustrates the seriousness of dipyrone-
induced agranulocytosis, highlights 
the risks associated with re-exposure 
and underlines the need for excellent 
communication between treating phy-
sicians and their patients. The possible 
underlying mechanisms, epidemiology 
and management of dipyrone-induced 
agranulocytosis are discussed.
Key words: agranulozytosis – metami-
zole – septic shock
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After the entrance with a single case (truly a worst case scenario), the pharmacovigilance 
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Abstract
Purpose Since the 1970s, the use of metamizole is controver-
sial due to the risk of agranulocytosis. The aim of this study
was to analyze individual case safety reports (ICSRs) of
metamizole-associated hematological adverse drug reactions
(ADRs).
Methods International and Swiss metamizole-associated
ICSR concerning selected hematological ADR were retrieved
from VigiBase™, the World Health Organization Global Da-
tabase of ICSR, and the Swiss Pharmacovigilance Database.
We evaluated demographic data, co-medication, drug admin-
istration information, dose and duration of metamizole treat-
ment, as well as the latency time of ADR, their course, and
severity. The subgroup analysis of Swiss reports allowed us to
analyze cases with fatal outcome more in depth and to esti-
mate a rough minimal incidence rate.
Results A total of 1417 international and 77 Swiss reports
were analyzed. Around 52 % of the international and 33 % of
the Swiss metamizole-associated hematological ADR oc-
curred within a latency time of ≤7 days. More women were
affected. The annual number of hematological reports and
those with fatal outcome increased over the last years parallel
to metamizole sales figures. In Switzerland, the minimal inci-
dence rate of agranulocytosis was 0.46–1.63 cases per million
person-days of use (2006–2012). Female sex, old age, pancy-
topenia, and co-medication with methotrexate were striking
characteristics of the seven Swiss fatal cases.
Conclusions Metamizole-associated hematological ADR re-
main frequently reported. This is underscored by increasing
annual reporting rates, which mainly reflect growing
metamizole use. Early detection of myelotoxicity and avoid-
ance of other myelotoxic substances such as methotrexate are
important measures for preventing fatalities.
Keywords Metamizole (dipyrone) . Agranulocytosis .
Hematological safety . Pharmacovigilance
Introduction
Metamizole, also known as dipyrone, is an old antipyretic and
analgesic drug with a controversial history. Although
metamizole has poor anti-inflammatory effects, it is often,
probably improperly, classified as a non-steroidal anti-inflam-
matory drug (NSAID). The pharmacological mechanism of
action is still not entirely understood. Inhibition of cyclooxy-
genase (COX) enzymes by metamizole has been demonstrat-
ed, but the corresponding IC50 values show a high variability
between 2.55 and >400 μmol/L (Ibuprofen: IC50 values
COX-1 12–42 μmol/L, Naproxen: IC50 value COX-1 0.3–
24 μmol/L) [1–4]. Other mechanisms of action have been
proposed, including stimulation of endogenous cannabinoid
receptors [5].
For years, the safety profile, in particular the risk of blood
disorders including agranulocytosis, has been controversially
discussed. Estimated incidences for agranulocytosis range
from 1:3000 users a year to 1:1,000,000 users a week [6, 7].
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Due to the risk of agranulocytosis, metamizole was banned or
withdrawn from the market in many countries (e.g. Great
Britain, USA, Sweden, Japan, and Australia), while it is
currently on the market in other countries and parts of the
world (Switzerland, Germany, France, Spain, Latin and South
America, Far East, and Africa) [8, 9].
Supporters of metamizole emphasize the advantages of
metamizole over classical NSAIDs, especially the better gas-
trointestinal and renal tolerability [10]. A meta-analysis of
several epidemiologic studies of serious adverse effects asso-
ciated with different analgesics demonstrated that the absolute
risk of mortality associated with metamizole is 25 deaths per
100 million users, which is in the same range as for paracet-
amol but much lower than for NSAIDs [11].
As the prescription rate of metamizole in Switzerland is
increasing and since we had received several reports of
metamizole-associated hematological adverse reactions, we
decided to analyze the international and Swiss hematological
pharmacovigilance data of this drug.
Methods
Study design and selection of individual case safety reports
This retrospective descriptive study is based on selected indi-
vidual case safety reports (ICSRs) from the World Health
Organization (WHO) global database VigiBase™ and, for a
more detailed subgroup analysis, from the Pharmacovigilance
database of the Swiss Drug Authority Swissmedic.We includ-
ed only ICSR with metamizole as suspected or interacting
drug associated with adverse drug reaction (ADR) terms
corresponding to the WHO adverse reaction terminology
(WHO-ART) “preferred terms” agranulocytosis ,
granulocytopenia, leucopenia, white blood cell abnormal not
otherwise specified, pancytopenia, anemia aplastic, aplasia
bone marrow, and marrow depression.
Recording of individual hematological case safety reports
International data
We received the coded data elements of the international
metamizole-associated ICSR from the WHO global database
VigiBase™ as a Microsoft Excel file. Since the international
ICSR did not contain a narrative, verification of coding,
adding codes or recoding could not be performed. The fol-
lowing data were analyzed: demographic data (age at ADR
onset and gender), route of administration, daily dose, dura-
tion of treatment, cumulative dose, reported ADR and their
causality assessments, latency time, duration of ADR, number
of suspected drugs, and total number of drugs. Using the
available coded dosage information, therapy and ADR dates,
we calculated the daily dose, cumulative dose, duration of
treatment, latency time, and duration of the ADR. The latency
time was defined as the period between the metamizole start
date and the date of ADR onset. For all international
metamizole-associated hematological ICSR, we analyzed the
annual reporting rate, reporting rate for fatal outcome, and
cumulative reporting rates stratified per country. ICSR with
unlikely or not assessable causality assessment or with a
negative latency time (ADR occurred before metamizole ad-
ministration) were excluded. If more than one metamizole
preparation was listed in a ICSR, we did not use the data
concerning the metamizole causality assessment, start and
stop date of metamizole treatment, outcome of reported
ADR, dechallenge and rechallenge information, or route of
administration for the final analysis due to difficulties in
handling the various data.
Swiss data
We received coded data elements of the Swiss metamizole-
associated ICSR from the pharmacovigilance database of
Swissmedic accompanied by the original ICSR with the case
narrative in a portable document file. The case narrative
contained more detailed information about the course of each
ADR and allowed us to analyze co-medication and cases with
fatal outcome more in depth. Additionally, we could estimate
a rough minimal incidence rate. We reviewed the information
of the case narratives and, in case of discrepancies between the
narrative and the coded information, we recoded according to
the narrative. The WHO-ART codes for reported ADRs were
first verified with the narrative according to the definitions for
blood dyscrasias [12, 13]. Afterwards, they were recorded as
follows: If in an ICSR, a patient had received neutropenia
(“preferred term”) with fever (preferred term), we recoded the
“included term” febrile neutropenia which belongs to the
preferred term agranulocytosis. We recoded the terms only,
if neutrophil counts were in accordance with the definition of
agranulocytosis [12, 13]. In cases with fatal outcome, we
recorded the day of death as the stop date of the ADR. In
cases without ADR stopping date, we added the date, if it was
obvious from the reported laboratory values or if it was
mentioned in the narrative. General statements of ADR
courses, for example “the hemogram improved within three
weeks” without an exact reported stopping date, were record-
ed as 21 days. Therapy options such as administration of
granulocyte-colony stimulating factor (G-CSF), antibiotics,
transfer of the patient to a hospital’s intensive care unit, or
withdrawal of the drug were also recorded.
For the calculation of the daily and cumulative dose, we
coded or recoded the data according to the narrative as fol-
lows: If possible, we calculated the daily and the cumulative
doses according to the coded dosage information. If
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metamizole was prescribed as an “as required”medication and
metamizole intake and dosage regimen could be assured, we
interpreted metamizole as being dosed maximally (4 g per
day). If the intake was uncertain or unknown, we did not
calculate the daily or cumulative dose for this ICSR. Cumu-
lative drug doses reported as circa 60 g were recorded as
exactly 60 g. A single administration of metamizole was
recorded as therapy duration of 1 day. Other possible coding
terms for time specification such as week(s), month(s), or
year(s) were counted as 7, 30, and 365 days, respectively.
When only the month and year (MM.YYYY) of the start or
stop date was reported, we counted the recorded month as a
full month (30 days). Coded time terms such as day(s), short
term, and long term without more specific explanations were
not used for the calculation of daily or cumulative dose or
therapy duration. For co-suspected drugs, we coded and
analyzed generic names and the corresponding ATC codes.
In addition to the annual reporting rate of metamizole-
associated hematological ICSR, we estimated a roughminimal
incidence for agranulocytosis using annual sales figures of all
Swiss metamizole preparations. The Swiss annual sales figures
were obtained from the respective marked authorization
holders. They were first expressed as defined daily dose
(DDD) and were pooled afterwards.
Statistical analysis
Descriptive analysis was performed using Microsoft Office
Excel (2010) and SPSS for Windows software (version 21).
For variables with normally distributed numeric values, the
arithmetic mean and standard deviation were calculated. For
variables without normally distributed values, median and
range were determined.
Results
Between June 22, 1968, and January 25, 2013, 1475 ICSR
concerning metamizole-associated hematological ADR were
transmitted to Vigibase™. After excluding ICSR according to
the defined exclusion criteria, 1417 international ICSR
remained for analysis. Between 1991 and December 31,
2012, the National Pharmacovigilance Center at Swissmedic
received 85 ICSR of metamizole-associated hematological
ADR. After the exclusion of ICSR using the previously de-
fined exclusion criteria, 77 ICSR remained for the subgroup
analysis.
Table 1 summarizes the findings of the international and
Swiss data. Concerning ADR terms, agranulocytosis was
listed most often in both datasets in almost one third of the
reports. This was followed by leucopenia in one fifth and
granulocytopenia in approximately 10 % of the reports. The
other terms concerned adverse drug reactions with a decrease
in all blood cell lines.
In both datasets, around two thirds of reports concerned
women and the median age was almost 60 years. When
stratified for age, there were no apparent differences between
international and Swiss cases, showing highest numbers in the
age group of 70–79 years (18–19 %) and lowest numbers of
ICSR in the age groups 0–9 years (1–2 %) and 10–19 years
(3–6 %). For detailed information about the age categories,
see supplemental Table 1. While 43 % (n=610) of the inter-
national cases were reported as serious, this number reached
90 % (n=69) for Swiss reports.
As shown in Table 2, the daily dose was within the recom-
mended range in both datasets. The duration of treatment
could be calculated for 765 international and 63 Swiss ICSR,
resulting in a median duration of 8 days (range 1 day to
9 years) and 13 days (range 1 to 594 days), respectively.
Among the 63 Swiss ICSR with known treatment duration,
almost half of the patients (44 %, n=27) received metamizole
for ≤7 days. As a consequence of the large range regarding
treatment duration, the corresponding cumulative doses also
showed a wide range. For 858 international ICSR, the latency
time could be calculated, resulting in a median of 7 days until
the diagnosis of the blood disorder, while the median latency
time in the Swiss ICSR was 14 days. In 442 (52 %) interna-
tional and 22 (33 %) Swiss hematological ICSR, the ADR
onset was within the first week after start of treatment. This is
shown in Fig. 1, which displays the latency time distribution
for the international ICSR stratified by weekly periods. The
latency time distribution of the Swiss reports was similar (data
not shown). The median number of concomitant drugs per
report was 3 and 4 in the international and Swiss dataset,
respectively. Also, the median number of suspected drugs
per report (including metamizole), was similar, namely 1 in
the international and 2 in the Swiss dataset. In 436 (31 %)
international ICSR, metamizole was reported as the only
suspected drug, whereas in the Swiss dataset, this was the
case in only 13 (17 %) reports. In Swiss reports, co-suspected
drugs were 28 anti-invective agents followed by 23 nervous
system drugs and 8 drugs for acid-related disorders (see sup-
plemental Table 2 for further information).
In the Swiss reports, causality for metamizole was never
judged as certain, unknown, or not assessable. In two thirds of
the reports, the causality for metamizole was judged as possi-
ble and in one third as probable. A rechallenge was reported in
45 (3 %) international ICSR. In rechallenged patients, the
ADR reoccurred in almost half of the cases (n=23). In 16
ICSR, the rechallenge outcome was unknown and in 6 ICSR,
the rechallenge was negative. None of the patients was
rechallenged in Switzerland.
In Switzerland, 31 (40 %) patients with metamizole-
associated hematological toxicity received G-CSF and 33
(42 %) patients were treated with antibiotics. Patients with
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G-CSF treatment had a mean duration of the ADR of 9 days
(n=31), whereas the patients without explicitly mentioned G-
CSF treatment showed a mean duration of 6.6 days (n=42). In
four cases, therapy with G-CSF was explicitly omitted. These
patients had a mean ADR duration of 9.5 days. The most often
reported underlying diseases in the Swiss dataset were
Table 1 Characteristics of international (1968-01/2013) and Swiss individual case safety reports (1991–2012) of metamizole-associated hematolog-
ical adverse drug reactions
Characteristics Total international ICSR (n=1417) Total subgroup of Swiss ICSR (n=77)
Reported hematological WHO-ART terms [number (%)]
Agranulocytosis 920 (57) 47 (61)
Leucopenia 349 (21) 12 (16)
Granulocytopenia 166 (10) 9 (12)
Pancytopenia 120 (7) 8 (10)
Anemia aplastic 29 (2) 1 (1)
Marrow depression 26 (2) NR
Aplasia bone marrow 18 (1) NR
WBC abnormal NOS 1 (0) NR
Female [number (%)] 876 (62) 51 (66)
Male [number (%)] 517 (36) 26 (34)
Age at ADR diagnosis [years; median (range)] 57 (1–96) 59 (9–96)
Fatal outcome [number (%)] 186 (13) 7 (9)
Total number of drugs per report [median (range)] 3 (1–53) 4 (1–19)
Number of suspected drug per report [median (range)] 1 (1–11) 2 (1–9)
Metamizole causality rating [number (%)] 1628 termsa (100) 77 terms (100)
Certain 104 (6) –
Probable 393 (24) 19 (25)
Possible 503 (31) 58 (75)
Not assessable 252 (15) –
Unknown 376 (23) –
aMore terms than cases due to more than one adverse drug reaction per report in some cases
NR not reported, ICSR individual case safety reports, NOS not otherwise specified, WBC with blood cell
Table 2 Metamizole administration information retrieved from international (1968-01/2013) and Swiss individual case safety reports (1991–2012) of
metamizole-associated hematological adverse drug reactions
Characteristics International ICSR (n=1417) Subgroup Swiss ICSR (n=77)
Daily dose [mg; (SD or range)] 2865 (2201) (n=196) 2226 (1169) (n=57)
Oral 1700 (500–10,000) (n=174) n.d.
Parenteral 4000 (500–12,000) (n=122) n.d.
Cumulative dose [g; median (range)] 20 (0.5–3048) (n=296) 19.5 (0.5–1188) (n=56)
Oral 22,6 (0.5–3048) (n=174) n.d.
Parenteral 18 (0.5–498) (n=122) n.d.
Route of administration [number (%)]
Oral 789 (60) 62 (81)
Parenteral 317 (24) 11 (14)
Duration treatment [days; median (range)] 8 (1–3303) 13 (1–594)
Latency time [days; median (range)]a 7 (1–3305) 14 (1–594)
The maximal daily dose of metamizole is 4000 mg
a Time from the start of the metamizole therapy till the adverse drug reaction was diagnosed
ICSR individual case safety reports, n number, n.d. not differentiated
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diseases of the circulatory system and injuries and diseases of
the musculoskeletal system (see supplemental table 3 for more
information).
Figure 2 shows the international annual reporting rate for
metamizole-associated hematological ADR and the reporting
rate of cases with fatal outcome. There was a first rise of the
international reporting rate in 2008 (76 ICSR) followed by a
remarkable increase in 2010 (219 ICSR). Most ICSR were
submitted by Germany (44 %), followed by Spain (35 %),
Switzerland (6 %), Italy (2 %), and Sweden (2 %). In Swit-
zerland, the annual reporting rate was stable until 2005 with
zero to two reports per year. Thereafter, the reporting rate
increased remarkably (2006: 7 reports; 2007: 6 reports;
2008: 2 reports; 2009: 5 reports; 2010: 16 reports; 2011: 14
reports; 2012: 15 reports). In total, 186 (13 %) metamizole-
associated hematological ICSR with fatal outcome have been
reported to the WHO, the first in 1968 and 85 since 2008. In
Switzerland, seven ICSR (9 %) with a fatal outcome were
reported, the first in 2006, two cases in 2011 and four in 2012.
The fatal Swiss cases are described in detail in supplementary
Table 4. Six of the 7 cases were women. The metamizole
dosagewas in the therapeutic range in all cases and the median
latency time until detection of the ADR was 14 days (range 4
to 594 days). In Table 3, characteristics of the seven Swiss
cases with fatal outcome were compared with the 70 surviving
cases. Among the cases with fatal outcome, there were more
females, more patients with triple blood cell line injury (43 %
versus 10 % among non-fatal cases), fatal cases were in
median 11 years older, and in 4 of the 7 fatal cases, there
was a co-treatment with methotrexate. Three of the four
patients with methotrexate therapy received an immunosup-
pressive low dose regimen and two of them had received only
one single dose of methotrexate. The proportion of certain
characteristics such as sex, number of affected cell lines, and
co-treatment with methotrexate were not statistically different
between patients with fatal outcome and surviving patients.
Finally, the Swiss annual reporting rates of metamizole-
associated agranulocytosis were compared with pooled Swiss
sales figures of all metamizole preparations on the Swiss
market. The sales figures were available from 2006–2012
and were converted to DDD. As shown in Fig. 3, the course
of these two variables was comparable during the observation
period, suggesting that the observed increase in ICSR is
mainly the result of growing metamizole use. Using the sales
figures, we could calculate minimal incidence rates. For
agranulocytosis, this was 0.46–1.63 cases per million
person-days.
Discussion
We evaluated data from the international pharmacovigilance
database Vigibase™ and Swiss ICSR regarding metamizole-
associated hematological ADR. In addition, the subgroup
analysis of the more detailed Swiss ICSR allowed us to
evaluate some specific issues such as comorbidities and co-
suspected drugs as well as analysis of fatal cases. Furthermore,
we could obtain a rough estimate of a minimal incidence rate
of metamizole-associated agranulocytosis in Switzerland.
Fig. 1 Latency times stratified by weekly periods for metamizole-
associated hematological adverse drug reactions among 858 reports
reported to VigiBase™, the WHO Global Database of Individual Case
Safety Reports (ICSRs), between 1968 and 01/2013
Fig. 2 International annual
cumulative reporting rate of
metamizole-associated
hematological adverse drug
reactions and reporting rate of
cases with fatal outcome,
retrieved from VigiBase™, the
WHO Global Database of
Individual Case Safety Reports
(ICSR), between 1968 and 01/
2013
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All age groups were affected by metamizole-associated
hematological ADR, although more ICSR for elderly people
(median age close to 60 years in both data sets) were reported.
An increased incidence of hematological disorders in older
patients has been reported in several population-based studies
of drug-induced agranulocytosis [14, 15]. However, since no
data about the exposure of specific age groups to metamizole
are available, our data do not allow the conclusion that
metamizole-associated hematological ADR occur more fre-
quently in older patients. Similarly, the reporting rate for
metamizole-associated hematological ADR was higher for
women than men, both in the Swiss and the international
ICSR dataset. This finding is in line with previous studies of
drug-induced agranulocytosis and, more specifically, also
with metamizole-associated agranulocytosis [8, 16, 17].
Again, our data support the results of these studies but do,
due to a lack of specific exposure data, per se not allow the
conclusion that metamizole-associated agranulocytosis is
more frequent in females.
The average daily dose in reported cases of metamizole-
associated hematological ADR was within the recommended
range according to the product information. This finding
argues against a typical dose-dependent toxicity of
metamizole and favors toxicity associated with the presence
of immunological or metabolic susceptibility factors in affect-
ed patients. Another important factor regarding the mecha-
nism of toxicity is the latency time, although this parameter
depends also on other factors than disease mechanism such as
frequency of blood monitoring, severity of symptoms, and/or
vigilance of doctors. Our data showed that in 33 % of the
Swiss and in 52 % of the international ICSR, hematotoxicity
appeared during the first week of treatment. In support of this
finding, a systematic review including 980 drug-associated
agranulocytosis case reports described a median metamizole
exposure of only 2 days until hematological abnormalities
appeared [18]. These findings are also in agreement with the
case control study of Ibanez et al. [19]. Furthermore, 88 % of
the Swiss ICSR and 96 % of the international hematological
ADR occurred within 2 months of metamizole treatment.
These findings agree well with a Swedish study, where 92 %
of the cases occurred within the first 2 months [8]. Interest-
ingly, these findings concerning metamizole are very similar
to those reported for clozapine, where >80 % of patients with
agranulocytosis were observed during the first 3 months of
treatment [20]. Considering the lack of accompanying immu-
nological features in most patients with metamizole-
associated myelotoxicity, both a metabolic and an immuno-
logical mechanism are possible.
In several European studies, the mortality rate of drug-
induced agranulocytosis decreased over the last years from
10 to 16 % to approximately 5 % [21]. This was considered
to be a consequence of the therapy with G-CSF and with
broad-spectrum antibiotics [8, 21]. Our data, however, do not
support this assumption. We observed an increase of reported
fatal cases in parallel with the increased reporting rate and use
of metamizole in Switzerland, despite the option for G-CSF
treatment. Since only 40 % of the Swiss patients were treated
with G-CSF, this finding may be explained by a selection bias.
It can be assumed that patients with more severe hematological
ADR were treated preferentially with G-CSF.
The reporting rate of metamizole-associated blood dyscra-
sias with fatal outcome in the Swiss and international dataset
increased over time, in particular in 2010 and 2011. The Swiss
data suggest that the increased use of metamizole is the main
reason for the increased number of reported fatal cases (see
Fig. 3). In their review, Andrès et al. listed age >65 years,
septicemia and/or shock, metabolic disorders such as renal
failure, and a neutrophil count below 0.1 G/L as poor prog-
nostic factors for drug-induced agranulocytosis [21]. These
risk factors could also be identified in the Swiss cases with
Table 3 Comparison of fatal and non-fatal Swiss individual case safety
reports of metamizole-associated hematological adverse drug reactions
between 1991 and 2012 (n=77)
Fatal Non-fatal
Total number of cases 7 70
Number of females 6 (86 %) 45 (64 %)
Age (years), mean (SD) 66 (22) 55 (21)
Daily dose (mg/day), mean (SD) 2286 (958) 2881 (2221)
Cumulative dose (g), median (range) 21 (10.5–1188) 19.5 (0.5–252)
Cumulative number of treatment days,
median (range)
14 (4–594) 13 (1–365)
White blood cell line affected, only 4 (57 %) 58 (83 %)
Two blood cell lines affected 0 (0 %) 5 (7 %)
All three blood cell lines affected 3 (43 %) 7 (10 %)
Number of cases with methotrexate as
co-suspected drug
4 (57 %) 0 (0 %)
The maximal daily dose of metamizole is 4000 mg
The percentages of certain variables (sex, number of affected cell lines,
co-treatment with methotrexate) were not statistically different between
patients with fatal outcome and surviving patients
SD standard deviation
Fig. 3 Annual reporting rate of metamizole-associated agranulocytosis
and the course of sold defined daily doses in Switzerland between 2006
and 2012
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fatal outcome. Five of the seven patients were over 65 years,
and patients with a fatal outcome were 11 years older than
those who recovered. In four of the seven fatal cases, septice-
mia was reported as cause of death and all fatal cases had
neutrophil counts below 0.1 G/L. Furthermore, the proportion
of patients in whom all three blood cell lines were affectedwas
higher among patients with fatal outcome than in those who
recovered.
Two additional potential risk factors for a fatal outcome
identified in our study are female sex and co-treatment with
methotrexate. In agreement with the overrepresentation of
females in the entire dataset, six out of the seven patients with
a fatal outcome were females. Importantly, methotrexate was
considered as co-suspected drug in four out of seven fatal
cases and in none of the non-fatal cases. Three of these
patients were on low-dose (immunosuppressive) methotrex-
ate, two of themwere on long-term treatment, and one of them
had received only a single dose. In addition, one patient with
T-cell lymphoma had been treated with an oncological dose
(single dose of 5500 mg) of methotrexate. In this patient,
methotrexate appears to be the more likely reason for
myelotoxicity than metamizole. Methotrexate-associated
myelotoxicity is dose-dependent. Since methotrexate is main-
ly eliminated by the kidney, impaired renal function is asso-
ciated with increased exposure and with an increased risk for
myelotoxicity [22]. Unfortunately, no serum creatinine con-
centrations have been reported or could be retrieved in patients
with low-dose methotrexate before the diagnosis of
myelotoxicity. Since low-dose methotrexate is used as an
immunosuppressant in autoimmune diseases such as rheuma-
toid arthritis and women are more likely to be affected by
autoimmune diseases, this may at least partially explain the
female predominance for fatalities in metamizole-associated
myelotoxicity.
Between 2006 and 2012, the pooled annual Swiss sales
figures of all metamizole preparations on the Swiss market
increased constantly by about 800,000 DDD per year. The
annual reporting rate for metamizole-associated agranulocy-
tosis also increased remarkably between 2006 and 2012, but
the absolute numbers remained small, with an annual
reporting rate for all blood dyscrasias between 2 and 16 and
for agranulocytosis between 2 and 12 reports per year. Over-
all, the annual reporting rates paralleled the sales figures and
therefore probably the use of metamizole in Switzerland,
although with annual fluctuations. These fluctuations can be
expla ined by changes in the repor t ing ra te for
pharmacovigilance data. This is influenced by many different
factors, in particular by underreporting and selective reporting
[23].
In 2002, Hedenmalm et al. [8] reviewed all spontaneous
reports of serious metamizole-associated blood dyscrasia in
Sweden and estimated the incidence for agranulocytosis asso-
ciated with metamizole to be 1 in 1439 prescriptions.
Similarly, Baeckerstroem et al. [24] analyzed spontaneous
reports of agranulocytosis and the use pattern of metamizole
in Swedish inpatients and outpatients. They calculated the risk
of metamizole-associated agranulocytosis to be approximate-
ly 1 in 31,000 metamizole-treated inpatients and 1 in 1400
outpatients. In our study, we were able to estimate a minimal
incidence rate for metamizole-associated agranulocytosis in
Switzerland using the annual reporting rates and annual
metamizole sales figures expressed as DDD. The estimated
incidence rate was 0.46–1.63 per million person-days, which
was within the range of the incidence rate in the International
Agranulocytosis and Aplastic Anemia Study (IAAA study) of
0.3–4.0 per million person-days [6, 8]. Our incidence rate is
higher than reported in a Polish study with an incidence rate of
0.2 per million person-days [16]. A detailed comparison with
the reported incidence rates of agranulocytosis in Sweden (at
least 1 per 1439 prescriptions) is not possible due to different
estimation methods and different units [8]. Taking into ac-
count the median treatment until agranulocytosis occurred
(13 days in Swiss patients) it can be assumed that the inci-
dence rate in Sweden is higher than in Switzerland. It has to be
considered, however, that the Swiss incidence rate may be
higher due to underreporting. It is well known that only
approximately 6 % of all ADR are spontaneously reported to
the pharmacovigilance systems [25].
Limitations
This study is based on spontaneously reported metamizole-
associated ICSR. As stated above, underreporting and missing
data in spontaneous reports are well-known problems in this
type of studies. Reasons for missing data are unavailable
information or the reporter did not consider certain facts as
relevant. Furthermore, the standardized requirements for
reporting ADR changed over the last decades, and the ICSR
include progressively more information. In addition, ICSR
derive from different sources (countries, National
Pharmacovigilance Centers and companies) and were written
and coded by different reporters with potentially different
coding policies. Therefore, heterogeneity of ICSR must be
taken into account when interpret ing data from
pharmacovigilance databases.
Conclusions
In patients treated with metamizole, we estimated an annual
incidence rate for agranulocytosis of 0.46–1.63 per million
person-days, which is within the range of the IAAA study [6].
This is a minimal risk, since underreporting is known to be
substantial for pharmacovigilance data. Female sex, triple
blood cell line dyscrasia, older age, and concomitant treatment
with methotrexate were identified risk factors for fatal out-
come. A large proportion of the Swiss (33 %) and the
Eur J Clin Pharmacol
international cases (52 %) occurred during the first 7 days of
metamizole treatment, compatible with an immunologic or a
toxic mechanism in predisposed patients. Taking into account
the rapid onset of metamizole-associated agranulocytosis,
close monitoring of the patient starting already in the first
week of treatment is essential to detect the onset of
myelotoxicity as early as possible. Information of the patients
to self-identify the first symptoms of myelotoxicity, to imme-
diately stop metamizole intake, and to consult a doctor may be
crucial to identify affected patients as soon as possible.
Metamizole prescribing should be conservative, and the pre-
scriber should outweigh the risk for myelotoxicity against the
adverse reactions of possible alternatives [11].
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Accompanying statement
The data for this work were obtained from the WHO Collaborating
Centre for International Drug Monitoring, Uppsala, Sweden and from
the Swiss health authority, Swissmedic, in Berne, Switzerland. Data from
spontaneous reporting are inhomogeneous as a result of different
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reporting policies worldwide and are vulnerable to underreporting and
reporting bias. The information contained in this work is therefore not
homogeneous, at least with respect to origin and also to likelihood that the
pharmaceutical product caused the adverse reaction. The conclusions
drawn based on these data do not necessarily represent the opinion of
the World Health Organization or of Swissmedic.
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3.2.1. Supplementary material: Hematological Safety of Metamizole: Retrospective 
Analysis of WHO and Swiss Spontaneous Safety Reports 
Supplementary Table 1 Age categories retrieved from international and the subgroup of Swiss individual case safety reports 
of metamizole-associated hematological adverse drug reactions between 1968-01/2013 and 1991-2012, respectively 
Supplementary Table 2 Drug classes of co-suspected drugs retrieved from the subgroup of Swiss individual case safety 
reports of metamizole-associated hematological adverse drug reactions between 1991-2012 
Age categories at ADR diagnosis 
[number (%)] 
Total international ICSR 
(n=1319) 
Total Swiss ICSR 
(n=77) 
< 10 years 22 (2) 1 (1) 
10 – 19 years 81 (6) 2 (3) 
20 – 29 years 163 (12) 11 (14) 
30 – 39 years 100 (8) 6 (8) 
40 – 49 years 164 (12) 10 (13) 
50 – 59 years 174 (13) 9 (12) 
60 – 69 years 234 (18) 13 (17) 
70 – 79 years 239 (18) 15 (19) 
> 80 years 142 (11) 10 (13) 
ADR adverse drug reaction, ICSR individual case safety reports, n number 
Drug classes of co-suspected drugs according to ATC codes 
[number] 
Total Swiss ICSR 
(n=77) 
Antiinfectives for systemic use 28 
Nervous system 23 
Cardiovascular system 14 
Others 13 
Antineoplastic agents and Immunomodulating agents 10 
Alimentary tract and metabolism 10 
Musculo – skeletal system 9 
ICSR individual case safety reports, n number 
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Supplementary Table 3 Most prevalent underlying diseases expressed as ICD-10 codes among 65 Swiss metamizole-
associated hematological individual case safety reports (ICSR) reported to Swissmedic between 1991-2012 
Organ classes Number (% of 
patients) 
Diseases (number of patients) 
Circulatory system 17 (26) Hypertension (9), cerebral disease (2), coronary 
heart disease (2), pulmonary disease (2), others (2) 
Injury and external causes 17 (26) Fractures (11), allergies (3), concussions (3) 
Musculoskeletal system 16 (25) Osteoporosis (4), rheumatoid arthritis (4), others (6) 
Endocrine and metabolic 
diseases 
14 (22) Diabetes (4), hypercholesterolemia (4), obesity (2), 
others (4) 
Symptoms unclassified 11 (17) Pain (8), others (3) 
Digestive system 10 (15) Not differentiated 
Infections 10 (15) Bacterial infections (3), bacterial infections 
unspecified (4), herpes zoster (1), viral encephalitis 
(1), hepatitis C infection (1) 
 
 
Supplementary Table 4 Detailed information on the seven Swiss individual case safety reports of metamizole-associated hematologic adverse drug reactions between 1991 and 2012 with fatal 
outcome 
Age 
sex 
Repor-
ting 
year 
Indication 
metamizole 
Underlying 
diseases 
Reported 
preferred term 
Metamizole 
causality 
assessment 
Daily dose, 
treatment 
duration, 
route of 
administration 
Latency 
timeb 
[days]
Therapy Co-suspected 
drugs 
Concomitant 
drugs 
Death 
cause 
Time 
to 
deatha
[days]
Labora- 
tory 
values 
21 
F 
2006 Abdominal 
pain 
Crohn's 
disease, bile 
stone with 
cholangitis or 
cholecystitis 
Agranulocytosis probable 1500 mg 
7 days 
oral 
10 GCSF, 
AB, W 
Azathioprine 
Mesalazine 
Methotrexate 
(single dose of 
25 mg) 
Paracetamol 
Pantoprazole Septicemia 
unspecified 
10 Neutro 
phils 
0.02 G/L 
78 
F 
2011 NR Atrial 
fibrillation 
and flutter, 
fracture of 
femur, 
rheumatoid 
arthritis 
Pancytopenia, 
gastrointestinal 
hemorrhage 
possible 1500 mg 
14 days 
oral 
14 GCSF, 
AB, W 
Alendronate 
Esomeprazole 
Etodolac 
Methotrexate 
(10 mg/week) 
Prednisolone 
Atenolol 
Calcium 
Colecalciferol 
Domperidone 
Flupentixol 
Lactitol 
Melitracene 
Morphine 
sulfate 
Gastroin-
testinal he-
morrhage 
unspecified 
10 Leucocytes 
0.3 G/L 
Thrombocytes 
12 G/L 
Hemoglobin 
43 g/L 
79 
M 
2011 Pain, not 
specified 
Multiple 
fractures of 
ribs 
Agranulocytosis possible 2000 mg 
9 days 
oral 
9 GCSF, 
AB, W 
- - Bacterial 
pneumonia, 
respiratory 
failure 
17 Leucocytes 
0.4G/L 
84 
F 
2012 Joint pain Rheumatoid 
arthritis, 
hyperuricemia 
Pancytopenia possible 2000 mg 
594 days 
oral 
594 GCSF, 
AB, W 
Allopurinol 
Methotrexate 
(7.5 mg/week) 
Moxifloxacin 
Spironolactone 
Torasemid 
- Multiple 
organ 
failure 
5 Neutrophils 
0.0 G/L 
Thrombocytes 
66 G/L 
Hemoglobin 
64 g/L 
AB antibiotics, F female, GCSF granulocyte colony-stimulating factor, M male, NR not reported, W Withdrawal of metamizole 
a Time from the diagnosis of the adverse drug reaction till death 
b Time from the start of the metamizole therapy till the adverse drug reaction was diagnosed 
Supplementary Table 4 (continued) Detailed information on the seven Swiss individual case safety reports of metamizole-associated hematologic adverse drug reactions between 1991 and 2012 
with fatal outcome 
Age 
sex 
Repor-
ting 
year 
Indication 
metamizole 
Underlying diseases Reported 
preferred term 
Metamizole 
causality 
assessment 
Daily dose, 
treatment 
duration, 
route of 
administration 
Latency 
timeb 
[days]
Therapy Co-suspected 
drugs 
Concomitant 
drugs 
Death 
cause 
Time 
to 
deatha
[days]
Labora- 
tory 
values 
66 
F 
2012 Fever of 
unknown 
origin 
Peripheral T-cell 
lymphoma, bacterial 
infection, viral 
encephalitis 
Pancytopenia possible 4000 mg 
4 days 
intravenous 
4 AB, W Amoxicillin 
Acyclovir 
Ceftriaxone 
Dalteparin 
Esomeprazole 
Methotrexate 
(single dose 
of 5500 mg in 
preexisting 
pancytopenia) 
Calcium 
folinate 
Escitalopram 
Glucarpidase 
Pantoprazole 
Prednisolone 
Septicemia 
unspecified 
13 Leucocytes 
1.62 G/L 
Thrombocytes 
64 G/L 
Hemoglobin 
84 g/L 
49 
F 
2012 Unspecified 
renal colic 
Nephrolithiasis, 
hypertension, 
hypercholesterolemia 
Agranulocytosis probable 3500 mg 
36 days 
oral 
56 GCSF, AB, 
tonsillectomy, 
W 
- Atorvastatin 
Candesartan 
Septicemia 
unspecified 
3 Neutrophils 
0.01 G/L 
83 
F 
2012 Low back 
pain 
Hypertension, 
fracture of pelvic 
ring, chronic lumbar 
pain 
Agranulocytosis possible 1500 mg 
120 days 
oral 
120 AB, W - Acetylsalicylic 
acid (100mg) 
Bisoprolol 
Calcium 
carbonate 
Colecalciferol 
Eprosartan 
Simvastatin 
Septicemia 
due to 
gram-
negative 
organism 
5 Leucocytes 
0.4 G/L 
AB antibiotics, F female, GCSF granulocyte colony-stimulating factor, M male, NR not reported, W Withdrawal of metamizole 
a Time from the diagnosis of the adverse drug reaction till death 
b Time from the start of the metamizole therapy till the adverse drug reaction was diagnosed 
38 
With the intense preoccupation of cases, we gained a better comprehension of 
hematological adverse drug reactions under metamizole. But for some questions, the lack 
of a control group makes final conclusions impossible. We therefore decided to compile 
data of control patients in addition to characterized cases managed at the University 
Hospital Basel. The question of how to find an appropriate control group was the crucial 
point. Finally, we split our cases in post-operative and non-post-operative cases and 
searched corresponding controls. 
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Abstract 
 
Purpose: The aim of this study was to identify possible risk factors for the development of 
leucopenia associated with metamizole use. 
Methods: A retrospective case-control study was performed. Cases of metamizole-
associated leucopenia managed at a single center (2005-2013) were characterized and 
compared to matched controls who took metamizole without developing complications. 
Results: Fifty-seven cases and 139 controls were identified. Of the cases, 32 were post-
operative (post-OP) and these were compared to age-, sex- and ward-matched post-OP 
controls (n= 64). The remaining cases (n= 25) were compared to sex-matched, non-post-OP 
controls (n= 75). The number of patients with a positive allergy history was higher among 
post-OP cases than controls (p= 0.0015) as was the number with previous leucopenic 
episodes (p= 0.03). The prevalence of diagnosed hepatitis C infection was 7% among all 
cases compared to 1% among all controls (p= 0.01). The use of concomitant cytostatic agents 
(even at immunosuppressive doses) was significantly higher among non-post-OP cases than 
controls (p= 0.007), with a trend to this distribution among post-OP patients.  
Conclusions: A history of allergies, leucopenic episodes, hepatitis C infection and 
concomitant cytostatic agents are possible risk factors leucopenia associated with 
metamizole use. 
 
 
 
Keywords: Metamizole (Dipyrone), Agranulocytosis, Leucopenia, Hematological Safety, Case-
control study, Risk factors
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Introduction 
Metamizole (dipyrone) is an old antipyretic and analgesic drug. Its safety profile - in 
particular the risk of blood disorders including agranulocytosis – is controversial. This has led 
many countries (including the United Kingdom) to withdraw or withhold metamizole from 
the market [1, 2]. However, in other countries such as Switzerland and Germany, 
metamizole is still frequently used and has even gained market share in recent years [3, 4], 
most likely due to its lack of hepatotoxicity and minimal renal toxicity. Routine monitoring of 
blood counts while under metamizole therapy is not common practice and is not included in 
the drug label [5]. The mechanism by which metamizole causes blood disorders has not yet 
been fully elucidated. Available data suggest an immunological process as well as direct 
toxicity towards the progenitor cells in the bone marrow [6]. 
In the 1980s, a large population-based case-control study examined the risk of 
agranulocytosis or aplastic anemia under treatment with several drugs including metamizole 
[7]. The study found that the incidence of metamizole-induced agranulocytosis varied 
markedly between countries. Little is known, however about the underlying risk factors for 
developing blood cell disorders under metamizole. If strong risk factors are found, these 
could be used to identify patients in whom metamizole should be avoided. Conversely, 
patients   who   do   not   possess   identified   risk   factors   may   benefit   from   metamizole’s  
advantages over other analgesic agents such as paracetamol and non-steroidal 
antiinflammatory agents. Metamizole would therefore be applied in a safer, more targeted 
fashion.  
A number of studies characterizing cases of metamizole-induced white blood cell 
disorders have been conducted [2-4], however as far as we know, no case-control studies 
have been performed. In the recently published study by Huber and colleagues, data of a 
prospective case-control surveillance study were used, but the presented results only 
contain data pertaining to the cases [4].  
The aim of the present study was therefore to compare cases of metamizole-associated 
leucopenia with control patients to identify possible risk factors for developing this 
complication and therefore to improve our knowledge about metamizole`s risk-benefit 
profile. 
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Methods 
This retrospective, descriptive case-control study examined cases of metamizole-
associated leucopenia which were managed at the University Hospital in Basel, Switzerland, 
between April 2005 and August 2013. Cases were either post-operative (post-OP) or non-
post-OP. In order to avoid confounding by selection, cases were compared to post-OP and 
non-post-OP controls. Post-OP cases were compared to age, sex, and ward matched post-OP 
control-patients who had received metamizole without complication between 2005 and 
2013. Non-post-OP cases were compared to sex-matched control patients who had received 
metamizole for at least four weeks between 2001 and 2014 in primary care settings in the 
Basel area without complication. The study was approved by the local ethics committee 
“Ethikkommission  Beider  Basel”   (protocol  number  EKBB  2013/130).  As  data  were  analyzed  
anonymously, no patient informed consent was required. 
 
Selection and assessment of cases 
The electronic medical records of the University Hospital Basel were screened for the 
keywords metamizole or Novalgin® in combination with agranulocytosis, neutropenia, or 
leucopenia. Additionally, the in-patient referrals to the hematology department which 
included the keyword Novalgin® were screened for metamizole-associated leucopenia. Cases 
with a strong temporal relationship between metamizole exposure and the development of 
laboratory-confirmed leucopenia (leucocyte count below 3.5 x 109/L) were included.  
We evaluated demographic data such as age at the time of diagnosis of the adverse drug 
reaction (ADR) and body mass index (BMI), underlying diseases, history of immediate- and 
delayed-type   hypersensitivity   reactions   (“allergy”),   co-medication, drug administration 
information (dose, route, frequency) as well as duration of metamizole therapy, latency time 
of the ADR, laboratory findings and the outcome and treatment of the ADR for each case. 
Co-medication with drugs known to be associated with acute agranulocytosis (level 1 
evidence according to Andersohn and colleagues) were taken into consideration when 
assessing  ADR  causality  [8]  and  were  named  “potentially  myelotoxic”.  The  concomitant  use  
of cytostatic agents (which cause dose-dependent myelotoxicity) such as cancer 
chemotherapeutic drugs or immunosuppressant-dose methotrexate (maximum 30 mg/week 
oral or subcutaneous) or azathioprine (maximum 5 mg/kg body weight per day) was also 
recorded. We assessed ADR causality according the Naranjo ADR probability scale which 
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includes assessment of other possible causes such as co-morbidities and co-medication [9]. 
Only  cases  with  an  at  least  “possible”  causality  assessment  according  the  Naranjo  scale  were  
evaluated further. 
Using the available dosage information, therapy and ADR dates, we calculated the daily 
dose, cumulative dose, duration of treatment, latency time and duration of the ADR. The 
latency time was calculated as the period between the metamizole start date and the date 
of ADR onset according to laboratory assessments as defined above. If metamizole was 
prescribed  as  an  ‘as  required’  medication  and  metamizole  intake  and  dosage  regimen  were  
not known with confidence, we recorded the mean of the minimal daily dose (500mg) and 
the  individual’s  maximal  prescribed  daily  dose  (14  of  57  cases).   
Full blood counts (hemoglobin, leucocyte- and platelet-counts) were recorded at the 
start date of the metamizole therapy, during metamizole therapy (controls) or when the 
leucocyte count reached its nadir (cases). Since metabolites of metamizole are mainly renally 
excreted and their accumulation in renal impairment might be a risk factor for the 
development of leucopenia, GFR estimated via the Chronic Kidney Disease Epidemiology 
Collaboration (CKD-EPI) formula [10] was assessed at the start of metamizole therapy and at 
the start of the ADR (cases) or before and during metamizole therapy (controls).  
 
Selection and assessment of controls 
Post-OP controls 
The electronic medical records of the University Hospital Basel were screened for post-
OP patients treated between 2005 – 2013 who received metamizole as post-OP analgesia 
and were discharged with a prescription for daily metamizole until resolution of pain. These 
patients were not known to develop any hematological complications. Two age- (±5 years), 
sex-, and ward-matched controls per post-OP case were randomly chosen from the list 
containing all possible controls (n= 21381) using a list randomizer provided by random.org 
[11]. We evaluated demographic data (sex, age at last intake, BMI), underlying diseases, 
history of allergy, co-medication, and if available, laboratory findings (full blood count and 
GFR) before and during metamizole therapy. Co-medication was evaluated in the same 
manner as for the cases. Cumulative metamizole dose and duration of treatment were not 
known because these patients were discharged home with a metamizole prescription. 
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Non-post-OP controls 
Non-post-OP controls were selected from an outpatient setting to ensure selection of 
patients who had been regularly exposed to metamizole for at least 4 weeks without 
developing hematological complications. The minimal duration of metamizole intake in this 
non-post-OP control group was chosen according to the latency time data from our previous 
pharmacovigilance study [3]. In this study, 84% of the cases occurred within 28 days of 
metamizole treatment. General practitioners in the Basel area were asked to identify 
patients attending during one reporting month (May 2013) who had taken metamizole 
continuously for at least 28 days (at least 500 mg per day) and who had not developed any 
obvious blood disorders. Due to the rarity of such controls, it was only possible to sex-match 
them with the cases. Data as outlined above for cases and post-op controls, where 
applicable, were recorded from the medical records.  
Using the available dosage information and therapy dates, we calculated the daily dose, 
cumulative dose, and duration of treatment of the corresponding episode of metamizole 
intake.  If  metamizole  was  prescribed  as  an  ‘as  required’  medication  and  metamizole  intake  
and dosage regimen were not known with confidence, the same method as described above 
was used. If the amount of metamizole that the patient obtained was known (dispensing 
practices), this was used for the calculation of the cumulative and daily dose. When only the 
month and year of the start date was reported, we counted the recorded month as a full 
month (30 days). In cases where several episodes of more than 28 days of metamizole intake 
with breaks between the episodes took place, only the longest episode was evaluated. The 
same laboratory values as in the case group were recorded, but at the nearest available date 
before the start date of metamizole as well as the newest values under the metamizole 
therapy. 
 
Statistical Analysis 
Descriptive analyses were performed using Microsoft Office Excel (Version 2010, 
Redmond, Washington, USA) and GraphPad PRISM (Version 6, La Jolla, California, USA). For 
variables with normally distributed numerical values, the arithmetic mean and standard 
deviation were calculated. For variables without normally distributed values, median and 
range were determined. Significance of differences between the cases and controls were 
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assessed using the Chi-square test, Fisher exact test for small numbers, and Mann-Whitney-
U test. Differences were considered as significant when p ≤  0.05.  
 
Results 
Fifty-seven cases of metamizole-associated leucopenia managed at the University 
Hospital Basel between April 2005 and August 2013 were included according to the defined 
inclusion criteria. Of these, 32 were post-OP and 25 non-post-OP. Sixty-four age, sex- and 
ward matched post-OP controls and 75 non-post-OP control patients from general practice 
settings were identified. In total 543 general practitioners were approached, 19 of whom 
provided 93 patients, from which 75 could be sex-matched to non-post-OP cases. 
 
Patient and metamizole treatment characteristics 
Table 1 summarizes the patient characteristics. The median age of the non-post-OP 
controls was higher than that of the non-post-OP cases. In keeping with the older age, the 
number of diagnoses and total number of co-medications per patient were also higher 
among those controls compared to non-post-OP cases. In contrast, among post-OP cases, 
the total number of diagnoses and co-medication was higher than among the age-, sex- and 
ward-matched controls.  
In the non-post-OP control group, metamizole was solely taken orally whereas in the 
corresponding case group, 20% received intravenous metamizole (Table 2). As also shown in 
Table 2 the mean daily metamizole dose did not differ significantly among non-post-OP 
cases and controls and was within the recommended range. The median treatment duration 
in the post-OP case group was 6 days and approximately two thirds of the cases took 
metamizole for 1-7 days. The median treatment duration in the non-post-OP case group was 
13 days with one third taking metamizole for 1-7 days. The non-post-OP controls took 
metamizole per definition for at least 28 days, one third for even longer than one year. 
 
Table 1 Patient characteristics 
Post-OP Cases 
(n=32) 
Post-OP Controls 
(n=64) 
p-value Non-post OP Cases 
(n=25) 
Non-post OP 
Controls (n=75) 
p-value 
Age [years; median (range)] 
At ADR diagnosis (cases) or at last intake (controls) 58 (16-82) 58 (16-82) 0.87a 51 (20-84) 79 (41-98) <0.001a 
Female [number (%)] 17 (53) 34 (53) 1b 19 (76) 57 (76) 1b 
Body mass index [kg/m2; median (range)]d 25 (20-45), n = 18 26 (18-56), n = 56 0.69a 21 (18-47), n = 11 28 (16-40), n = 51 0.18 a 
Co-morbidities  
Total number of diagnoses [median, (range)] 5 (1-9) 2 (0-10) <0.001a 4 (1-9) 6 (2-11) 0.0060a 
Number of chronic diseases [median, (range)] 2 (0-5) 2 (0-10) 0.52a 3 (0-6) 4 (1-9) 0.0014a 
Number of patients with known allergy [number (%)] 16 (50) 12 (19) 0.0015b  8 (32) 18 (24) 0.43b 
Previous leucopenic episodes [number (%)]e 3 (9) 0 (0) 0.03c 1 (4) 0 (0) 0.25c  
Underlying Hepatitis C infection [number (%)]f 3 (9) 1 (2) 0.1c 2 (8) 0 (0) 0.061c 
Co-medication 
Total number of co-medications [median, (range)] 9 (1-18) 5 (1-18) 0.0024a 6 (1-18) 9 (0-19) 0.047a 
Patients concomitantly receiving non-chemotherapeutic 
potentially myelotoxic co-medicationg [number (%)] 
10 (31) 22 (34) 0.76b 7 (28) 33 (44) 0.16b 
Patients concomitantly receiving cytostatic agents 
[number (%)]h
3 (9) 3 (5) 0.40c 6 (24) 3 (4) 0.007c 
aMann-Whitney U Test, bChi-Square test, cFisher exact test dIn cases where the current body weight was missing, the last known value (last observation carried 
forward method) was used to calculate the BMI epancytopenia n=3, bicytopenia (anemia and neutropenia) n=1 fserology performed during admission in five non-
post-OP cases and in seven post-OP-cases and in four post-OP controls gDrugs with evidence 1 level for causing acute agranulocytosis (table 2) according 
Andersohn, et al 2007 hcytostatic agents included immunosuppressive-dose methotrexate, azathioprine and cancer chemotherapeutic drugs (see Supporting 
Table II for detailed information) 
Table 2 Characteristics of metamizole therapy 
Cases post-OP (n=32) Controls post-OP (n=64) Cases non-post-OP (n=25) Controls non-post-OP 
(n=75) 
Formulation  
Oral, number of patients (%) 12 (38) 64 (100) 14 (56) 75 (100) 
Intravenous, number of patients (%) 12 (38) 10 (16)b 5 (20) 0 (0) 
Unknown, number of patients (%) 8 (25) 0 (0) 6 (24) 0 (0) 
Mean (SD) daily dose (g) 2.19 (1.22) n= 27 na 1.99 (1.27) n=17 1.76 (0.82)a  
Median (range) cumulative dose (g) 13.50 (0.5-94) n=25 na 21.6 (1-82.5) n=14 316 (24-3109) 
Median (range) treatment duration (days) 6 (1-59) n= 29 na 13 (1-365) n= 16 187 (32-2192) 
Number of patients treated for: 
1 to 7 days (%) 18 (62) na 5 (31) n/a 
8 to 30 days (%) 8 (28) na 8 (50) n/a 
31 to 60 days (%) 3 (10) na 1 (6) 11 (15) 
61 to 120 days (%) 0 (0) na 1 (6) 18 (24) 
121 to 180 days (%) 0 (0) na 0 (0) 6 (8) 
180 to 365 days (%) 0 (0) na 1 (6) 14 (19) 
> 365 days (%) 0 (0) na 0 (0) 26 (35) 
aMann-Whitney U Test compared to cases non-post-OP p = 0.88, b i.v. administration followed by per oral administration 
n/a not applicable, na not available 
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Characteristics of the leucopenia 
Figure 1 shows the leucocyte and neutrophil values for the case and control subgroups; 
all cases experienced a distinct fall in leucocyte and neutrophil counts. Leucocyte counts 
measured whilst under treatment with metamizole were available for 72% of post-OP 
controls. Pre- and during- metamizole exposure leucocytes were available for 53% and 52% 
of post-OP and non-post-OP controls, respectively. Among non-post-OP controls, 69% had a 
during-treatment leucocyte count result, all of which were above the lower normal range. 
The values confirmed the clinical observation that metamizole was well tolerated (Figure 1). 
Regarding hemoglobin and platelet counts, no trend was seen (Supporting Figure 1).  
Table 3 shows the ADR characteristics among the cases. No cases fulfilled the criteria for 
a   “definite”   causality   assessment   according   the  Naranjo   scale.   The   three   cases   that  had  a  
recurrence  of  the  ADR  on  rechallenge  would,  however,  have  been  classified  as  “certain”   if  
the WHO–UMC Probability Scale had been applied [12].  
The ADR appeared during the first week of treatment in 40% and during the first two 
months in 93% of all cases. Nineteen patients (33%) were known to have been treated with 
granulocyte colony stimulating factor (G-CSF).  
Four cases in the present study had a fatal outcome. In two of them, metamizole was 
assessed as probably being causal and in the other two as possibly causal because 
concomitant methotrexate and azathioprine, respectively, were also suspected. All fatal 
cases were females (22, 71, 75, and 76 years old). One patient in the case group was recently 
reexposed to metamizole and had a fatal outcome [13].  
49 
Figure 1 Leucocyte and neutrophil counts before starting metamizole and at time of diagnosis of ADR (case groups A-D) or 
at last follow-up whilst taking metamizole (control groups E-H). Red lines indicate upper and lower reference values (10 - 
3.5 x 109/L for leucocytes and 6.7 - 1.3 x 109/L for neutrophils, respectively). ADR adverse drug reaction; n number 
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Table 3 Characteristic of the white blood cell disorders (all cases) 
  All cases (n=57) 
Naranjo Causality assessment [number (%)]  
Definite 0 (0) 
Probable 20 (35) 
Possible 37 (65) 
Rechallenge information [number (%)]  
Known positive rechallenge 3 (5) 
Known negative rechallenge 2 (4) 
Rechallenge with unknown outcome 1 (2) 
No known rechallenge 51 (89) 
Timing of ADR n=49 
During therapy [number (%)] 31 (63) 
1-7 days after last application [number (%)] 14 (29) 
8-14 days after last application [number (%)] 2 (4) 
> 14 days after last application [number (%)] 2 (4) 
Latency timea [days; median (range)] 11 (1-368) 
ADR duration [days; median (range)]  
With G-CSF (n= 16)  5.5 (1-20) 
Without G-CSF (n= 21) 5 (1-21)  
Unknown whether G-CSF given or not (n= 12) 5 (1-51)  
Time between ADR onset and nadir [days; median (range)] 1 (0-36) 
Time between nadir and recovery [days; median (range)] 4 (1-19) 
With G-CSF (n= 16) 3.5 (1-19) 
Without G-CSF (n= 21) 4 (1-13) 
Unknown whether G-CSF given or not (n= 12) 4 (1-16) 
Time between stopping metamizole and recovery in cases where ADR 
occurred during metamizole therapy [days; median (range)] 
 
With G-CSF (n= 9) 5 (1-29) 
Without G-CSF (n= 15) 4 (1-19) 
Unknown whether G-CSF given or not (n= 2) 6.5 (6-7) 
Degree of Leucopenia (n=56)  
Leucocytes 2-3.5 x 109/L [number (%)] 18 (32) 
Leucocytes 1-2 x 109/L [number (%)] 22 (39) 
Leucocytes <1 x 109/L [number (%)] 16 (29) 
Degree of Neutropenia (n=55)  
Neutrophils 1-1.3 x 109/L [number (%)] 10 (18) 
Neutrophils 0.5-1 x 109/L [number (%)] 19 (35) 
Neutrophils <0.5 x 109/L [number (%)] 26 (47) 
Outcome [number (%)]  
Recovered 53 (93) 
Died 4 (7) 
atime between starting metamizole and the onset of the ADR 
ADR adverse drug reaction, G-CSF granulocyte colony stimulating factor 
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Co-morbidities and their association with the ADR 
Figure 2 shows the course of the GFR at the start of metamizole therapy and at the start 
of the ADR in the case groups. The GFR did not change significantly between these two time 
points, whether in post-OP cases nor in the non-post-OP cases. Likewise, the GFR did not 
change in the control groups and under metamizole therapy. Three patients in the case 
group (1 post-OP and 2 non-post-OP cases) and one patient in the non-post-OP control 
group had preexisting severe renal impairment (GFR < 30 mL/min/1.73m2) at the start of the 
metamizole therapy. However, the GFR increased or remained clinically stable during the 
metamizole therapy in all cases (from 16 to 61.2 mL/min/1.73m2, 24.4. to 34.0 
mL/min/1.73m2, from 21.5 to 28.3 mL/min/1.73m2 and from 27.3 to 22.0 mL/min/1.73m2 
respectively).  
 
Figure 2 Estimated glomerular filtration rate (eGFR) at the start of metamizole therapy and at ADR start (case groups, left 
side), eGFR before the start of metamizole therapy and under metamizole therapy (control groups, right side). ADR adverse 
drug reaction; n number; n.s. not significant  
52 
 
Patients with a history of allergy (Table 1) were also analyzed in more detail (Supporting 
Table 1). The number of known medication and non-medication allergies was significantly 
higher in the post-OP case group compared to the corresponding control group (p= 0.007 
and 0.014, respectively). Among non-post-OP cases and controls, there was a non-
statistically significant trend towards a higher prevalence of allergies among cases compared 
to controls. Specifically, the number of patients with beta-lactam allergies was significantly 
higher (p= 0.02).  
Patients with a history of previous leucopenias (Table 1) were analyzed in more detail. 
One patient (a post-OP case) had a preexisting bicytopenia (recurrent episodes of anemia 
and neutropenia) of unknown origin. The neutropenia re-emerged under metamizole and 
resolved again after stopping metamizole. In three cases (2 post-OP and 1 non-post-OP), a 
preexisting recurrent pancytopenia of uncertain origin had previously been diagnosed. In all 
of these cases, the leucocyte or neutrophil counts fell from a value within the normal range 
to a value below the lower limit of normal under metamizole. Three other cases had a 
preexisting hematological condition (one patient had hemophilia B, one patient had an 
isolated factor VII deficiency and another chronic myelocytic leukemia).  
Five patients in the case group (3 post-OP and 2 non-post-OP cases) and one control 
patient were hepatitis C positive. Analyzing data from all cases and all controls together, 
there were significantly more patients with underlying hepatitis C infection among cases 
than controls (p= 0.008). One patient with an underlying hepatitis C infection was co-
infected with hepatitis B and another with hepatitis B and HIV. No other viral infectious 
diseases were known to be present in either the case or the control groups.  
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Co-medication and their association with the ADR 
The total number of patients concomitantly treated with potentially myelotoxic co-
medication was similar in all groups (p= 0.76 in post-OP cases and controls and p= 0.16 in 
non-post-OP cases and controls, respectively) (Table 1). Potentially myelotoxic and cytostatic 
co-medication are listed in detail in the supporting Table 2. In 54% of all cases, co-
medication other than metamizole could potentially have also caused or contributed to the 
ADR, however these were taken into consideration when determining the Naranjo score. 
The number of patients treated with concomitant cytostatic agents did not differ 
significantly in the post-OP case and control group (Table 1). However, in the non-post-OP 
groups, a greater proportion of cases than controls received concomitant cytostatic agents 
(p= 0.007).  
 
Discussion 
This retrospective study of metamizole-associated leucopenia identified a number of 
different possible risk factors, which might allow targeted and safer metamizole use. This is 
of particular interest in view of the increasing use of metamizole in central European 
countries such as Switzerland and Germany.  
Previous population-based studies of drug-induced agranulocytosis found a high 
incidence among older patients [14, 15]. Firm conclusions, however, can only be drawn if the 
exposure data of specific age groups is known. Considering the current study, the 
significantly higher age of the non-post-OP controls does not support the assumption that 
age is a real risk factor for metamizole-induced leucopenia.  
The opposing findings regarding the total number of diagnoses and concomitant 
medication among post-op and non-post-op cases and controls likely reflects the inability to 
age-match in the non-post-OP groups. As the findings are in opposition, we do not believe 
the total number of diagnoses or total number of co-medication are risk factors for the 
development of metamizole-associated leucopenia. 
Whether intravenous administration is a risk factor - which the data from the post-OP 
patients might suggest - or not, cannot be fully assessed in this study because the non-post-
OP controls were never candidates for intravenous therapy.  
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The fact that the daily doses in the non-post-OP case and control groups were similar is 
evidence against a typical dose-dependent toxic effect; rather it favors toxicity associated 
with the presence of immunological or metabolic susceptibility factors in affected patients. 
The median latency time of 11 days between the start of the metamizole therapy and the 
onset of the ADR (Table 3) lies within the 7-14 day latency time found in a previous study 
analyzing pharmacovigilance data [3]. Similarly, the ADR appeared within the previously 
described time-frame of the pharmacovigilance data study of 1417 reported cases of 
metamizole-induced white blood cell disorders [3] and are in agreement with other previous 
studies [8, 16]. These findings would support routine blood count monitoring during the first 
weeks of metamizole therapy. The duration of the ADR was approximately 5 days, 
independent of the use of G-CSF. This finding has to be interpreted in the light of the fact 
that the more severe cases tended to preferentially receive G-CSF, despite the paucity of 
data supporting the benefit of G-CSF in this setting. 
No changes in GFR were seen under metamizole and there was no difference in GFR 
between the case and control groups (see Figure 2). Renal impairment was therefore not 
found to be a risk factor for the development of metamizole-induced leucopenia in the 
present study. 
If the mechanism of toxicity has an immunological component, another possible risk 
factor could be a susceptibility to allergies, which our findings support. A significantly higher 
prevalence of allergies among non-post-OP cases compared to controls was not seen as it 
was in the post-OP setting, merely a trend. This may reflect different data recording 
practices in hospital compared to general practice. The post-OP groups – all of which were 
inpatients in the same hospital – however, underwent the same documentation process, so 
their data is more comparable. New concepts of immunological mechanisms like the p-i-
concept where drugs or metabolites interact directly with T-cells may help to understand 
mechanisms of toxicity, which cannot easily be categorized into classical known mechanisms 
[17]. A genetic predisposition – which could not be examined in this study - may also be 
relevant.  
Of special interest were the cases with preexisting hematological conditions, especially 
previous leucopenia. In two of the four patients with previous leucopenia, the likeliest cause 
was liver disease due to hepatitis C infection. In the other two patients, no reason for the 
peripheral leucopenia could be found in the bone marrow study. Whether underlying 
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hematological conditions make patients more vulnerable to the hematotoxic effects of 
metamizole cannot be conclusively assessed here. However, these data suggest that 
preexisting hematological conditions are a possible risk factor. 
Our observation regarding an increased prevalence of hepatitis C infection in patients 
who developed a metamizole-associated white blood cell disorder compared to controls is in 
keeping with the increased risk of ADR in the setting of viral infection seen with other drugs 
[18]. An increased risk for developing ADRs has been shown in the setting of HIV, hepatitis C, 
EBV, HSV, HHV and CMV infection [19-22]. Asymptomatic carriers of hepatitis B with normal 
liver function tests were found to have impaired clearance of metamizole via oxidative 
pathways compared to healthy controls, leading to increased exposure to the 4-
methylaminoantipyrine metabolite (carriers and controls all had slow acetylator phenotype) 
[23]. In Western Europe, the prevalence of hepatitis C infection is estimated as 2.4% [24]. 
Overall our case group showed a prevalence of 7% and the control group a prevalence of 1%. 
The exact mechanisms whereby viral infections cause an increased risk of ADR are not fully 
known, but could be caused by any combination of a reduction in immune tolerance, 
increased antigenicity or altered drug metabolism [18].  
Regarding the co-administration of other bone-marrow toxic drugs, it is not always 
possible to separate out the impact the different drugs have on the ADR. This led to 54% of 
the cases having other co-medications which may or may not have contributed to the ADR. 
However, the administration of non-chemotherapeutic, potentially myelotoxic co-
medication was not different between both types of cases and controls. Concomitant use of 
cytostatic agents was more common among cases than their respective controls. Among 
non-post-OP patients this difference was statistically significant, indicating that the 
concomitant use of cytostatic agents might be a risk factor for the development of a white 
blood cell disorder under metamizole therapy. In the pharmacovigilance data study, co-
administration of methotrexate was identified as a risk factor for a fatal outcome [3]. In this 
current study, two fatalities involving concomitant immunosuppressive-dose methotrexate 
and azathioprine, respectively, occurred.  
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Limitations 
Retrospective studies are associated with a number of limitations. The problem of 
missing data is one important aspect and may have led to the inclusion of control patients 
who might have gone on to develop a white blood cell disorder under metamizole, especially 
in the post-OP control group. Furthermore, the limited number of study subjects due to the 
rarity of the ADR as well as the limited number of patients who take metamizole on a long-
term basis reduces study power. It is also possible that some cases were missed due to 
varying documentation policies. The inclusion of possible rather than only confirmed cases 
according to the Naranjo scoring system may have led to the inclusion of some cases where 
metamizole was not the likeliest cause of the white blood cell disorder. Lastly, the true 
prevalence of hepatitis C was not known as hepatitis C testing is not routinely performed in 
either the in-patient or general practice setting.  
 
Conclusion 
A history of allergy, previous leucopenic episodes, infection with hepatitis C and concomitant 
use of cytostatic agents (including at immunosuppressive doses) might be risk factors for 
metamizole-induced leucopenia and require further study. We suggest avoiding metamizole 
in such patients unless the benefits clearly outweigh the risks, in which case close blood-
count monitoring should be performed. In general, metamizole should always be prescribed 
on a case by case basis balancing the risk for myelotoxicity against the ADR profiles of 
alternative analgesic agents. 
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3.3.1. Supplementary material: Metamizole-induced Leucopenia: a Case-Control Study 
Supporting Table 1 Allergy history 
Post-OP cases 
(n=32) 
Post-OP controls 
(n=64) 
p-value Non-post-OP 
cases (n=25) 
Non-post-OP 
controls (n=75) 
p-value 
Patients with known medication allergies 
[number (%)] 
13 (41) 10 (16) 0.007 a 6 (24) 15 (20) 0.67a 
Median number of trigger drugs in patients with 
medication allergies (range) 
3 (1-6) 1 (1-3) 1 (1-2) 1 (1-4) 
Trigger drugs [number (%)]:  
Beta-lactam Total 9 (28) 6 (9) 0.02a 3 (12) 8 (11) 1b 
With skin reaction 5 2 2 4 
With anaphylactic 
reaction (dyspnea) 
1 - 1 - 
With unknown 
reaction 
3 4 - 4 
Other antibiotics 4 1 - 3 
NSAID 4 4 1 5 
Opioids 1 - 1 2 
Others 5 3 2 6 
Patients with known non-medication allergy 
[number (%)] 
7 (22) 3 (5) 0.014b 4 (16) 3 (4) 0.063b 
Allergic rhinitis 4 - 1 1 
Other allergies 5 3 3 1 
Not specified allergy - - - 1 
aChi-Square test, bFisher exact test 
NSAID non-steroidal antiinflammatory drug 
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Supporting Table 2 Co-medication known to be associated with agranulocytosis 
Post-OP cases 
(n=32) 
Post-OP controls 
(n=64) 
Non-post-OP 
cases (n=25) 
Non-post-OP 
controls (n=75) 
Total number of co-medication 286 368 185 688 
Patients concomitantly receiving cytostatic agents [number 
(%)]  
Methrotrexate (low-dose) 2 (6) 3 (5) 3 (12) 2 (3) 
Azathioprine - - 2 (8) - 
Gemcitabine - - - 1 (1) 
Sorafenib - - 1 (4) - 
Ipilimumab 1 (3) - - - 
Cisplatin/5-Fluorouracil - - 1 (4) 1 (1) 
Patients concomitantly receiving non-chemotherapeutic 
potentially myelotoxic co-medicationga [number (%)] 
Clopidogrel 1 (3) 2 (3) - 3 (4) 
Diclofenac - - - 3 (4) 
Fluoxetine 1 (3) - - 3 (4) 
Ibuprofen 5 (16) 13 (20) 4 (16) 3 (4) 
Ramipril 2 (6) 4 (6) 2 (8) 15 (20) 
Spironolactone 1 (3) 1 (2) - 7 (9) 
Co-prescribed drugs for which an association with the ADR 
could not be ruled out [number (%)] 
Beta-lactam antibiotics 
Amoxicillin/Clavulanic acid 6 (19) 3 (5) 2 (8) 1 (1) 
Tazobactam/Piperacillin 10 (31) - 2 (8) - 
Flucloxacillin 2 (6) - 1 (4) - 
Cefepim 1 (3) 1 (2) - - 
not specified 2 (6) - 1 (4) - 
Other antibiotics 
Ciprofloxacin 4 (13) 3 (5) 1 (4) 1 (1) 
Moxifloxacin 1 (3) - - - 
Vancomycin 7 (22) - - - 
Tobramycin 1 (3) - - - 
Proton-pump inhibitors 
(Es-)Omeprazole - 9 (14) 2 (8) 11 (15) 
Pantoprazole 2 (6) 28 (44) 1 (4) 39 (25) 
Other drugs 
Quetiapine 1 (3) 2 (3) 1 (4) 6 (8) 
Acetylsalicylic acidb - 9 (14) 1 (4) 22 (29) 
Mesalazine - - 1 (4) - 
Rifampicin 2 (6) - - - 
Interferon - - 1 (4) - 
Gabapentin - 1 (2) 1 (4) 3 (4) 
Mirtazapine - 2 (3) 1 (4) 4 (5) 
Haloperidol 1 (3) - - - 
Caspofungin 1 (3) - - - 
Pregabalin - 2 (3) 1 (4) 7 (9) 
Phenytoin 1 (3) 1 (2) - - 
aDrugs with evidence 1 level for causing acute agranulocytosis (table 2) according Andersohn, et al 2007 
bNon-post-OP Case: analgesic dose; Non-post-OP controls: 20 cardiac doses, 1 analgesic dose, 1 unknown dose 
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Supporting Figure 1. Hemoglobin and platelet counts before starting metamizole and at time of diagnosis of 
ADR (case group A-D) or at last follow-up whilst taking metamizole (control group E-H). ADR adverse drug 
reaction; n number    
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So far, the focus of our projects lay on the risks of metamizole. But for a proper evaluation 
of the safety profile, also the benefits of a drug have to be considered. An important 
question for clinicians is the question of renal tolerability of a substance. Especially for 
metamizole as a possible alternative for NSAIDs that are contraindicated in patients with 
renal insufficiency. The following clinical study should provide data for a more evidence-
based use of metamizole in such situations and may deliver information about the renal 
pharmacology of this drug. 
 
  
64 
 
 
 
 
3.4. Effect of metamizole (dipyrone) on renal function in salt-
depleted healthy subjects 
 
Lea S Blaser1, Urs Duthaler1,2, Jamal Bouitbir1,2, Anne B Taegtmeyer1,3, Evangelia Liakoni1,3, 
Stephan Krähenbühl1,2,3, Manuel Haschke1,2,3 
 
1 Division of Clinical Pharmacology & Toxicology, University Hospital Basel, Switzerland 
2 Department of Biomedicine, University of Basel, Switzerland 
3 Department of Clinical Research, University of Basel, Switzerland 
 
 
 
 
 
 
 
 
 
 
 
 
Unpublished  
65 
 
 
List of nonstandard abbreviations 
 
4-AA  4-aminoantipyrine 
4-AAA  4-N-acetylaminoantipyrine 
4-FAA  4-N-formylaminoantipyrine 
4-MAA  4-N-methylaminoantipyrine 
AUC  area under the concentration–time curve 
AUC0-5h partial area under the concentration-time curve from 0 to 5 hours 
AUC0-24h partial area under the concentration-time curve from 0 to 24 hours 
AUEC  area under effect curve 
Cmax  peak plasma concentration 
COX  cyclooxygenase 
CTCAE  common terminology criteria for adverse events 
GFR  glomerular filtration rate 
NSAID(s) nonsteroidal anti-inflammatory drug(s) 
Tmax  time to reach peak plasma concentration 
λz  terminal elimination rate constant 
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Abstract 
Introduction: The antipyretic and analgesic metamizole (dipyrone) is supposed to have 
better renal tolerability than NSAIDs, but there is little data available supporting this 
assumption. 
Aims: The primary aim was to investigate the effect of metamizole on inulin clearance and 
urinary excretion of sodium and of the prostacyclin metabolite 6-keto-PGF1α in healthy, salt-
depleted, volunteers. A secondary aim was to obtain pharmacokinetic data of the four major 
metamizole metabolites and to correlate these data with pharmacodynamic effects. 
Methods: Subjects received a diet containing 50 mmol sodium/day one week before and 
during treatment with metamizole (1000 mg TID, n=8) or naproxen (500 mg BID, n=7) for 7 
days. Investigations were performed after single dose (day 1) and after repetitive dosing 
(day 7). 
Results: After single and repetitive dosing, neither metamizole nor naproxen had a 
significant effect on inulin clearance or sodium excretion. After repetitive dosing, there was 
a trend for decreased sodium excretion after naproxen but not after metamizole. Both 
metamizole and naproxen inhibited renal 6-keto-PGF1α excretion starting 2 hours after 
ingestion and lasting the entire dosing period during repetitive dosing. The two active 
metamizole metabolites (4-methylaminoantipyrine, 4-MAA and 4-aminoantipyrine, 4-AA) 
had half-lives of 3.7 (4-MAA) and 5.8 h (4-AA), respectively and they accumulated 
approximately 1.5 and 3 times after 7 days of repetitive dosing. 
Discussion: Metamizole inhibits renal excretion of 6-keto-PGF1α similar to naproxen, 
suggesting that metamizole inhibits renal prostaglandin synthesis. Nevertheless, in healthy, 
sodium-depleted subjects, metamizole had no significant effect on inulin clearance or renal 
sodium excretion, whereas there was a trend to a decreased sodium excretion after 
repetitive naproxen dosing.  
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Introduction 
The antipyretic analgesic metamizole (dipyrone) is supposed to have a better renal 
tolerability than nonsteroidal anti-inflammatory drugs (NSAIDs), but there is little data 
available to support this assumption [1, 2]. The mechanism of action of metamizole is 
currently not entirely established. Inhibition of cyclooxygenase (COX) enzymes by 
metamizole or metamizole metabolites has been demonstrated, but the reported IC50 for 
COX-1   inhibition   shows   high   variability   ranging   from   2.6   μmol/L   to   >400   μmol/L   (in  
comparison IC50 for COX-1 for ibuprofen 12-42  μmol/L,  and  for  naproxen  0.3-24  μmol/L)  [3-
6]. Similarly, the reported IC50 for COX-2 inhibition by metamizole show high variability 
ranging   from  4.7  μmol/L   to  >400  μmol/L   [4, 5, 7]. Other mechanisms of action have been 
proposed, including stimulation of endogenous cannabinoid receptors [7, 8], involvement of 
glutamatergic mechanisms, inhibition of neurokinin-1 mediated responses, inhibition of the 
protein kinase C-dependent pathway [9], and involvement of the descending serotonergic 
and noradrenergic systems [10]. Regarding safety, the most often mentioned problem of 
metamizole is agranulocytosis (neutrophil count <500/µL), representing a severe and 
potentially life-threatening adverse drug reaction [11]. Additionally, metamizole can cause 
infusion reactions with severe hypotension, especially after rapid infusion of high doses [12].  
On the other hand, metamizole shows several advantages compared to NSAIDs. 
Gastrointestinal toxicity is the most common adverse reaction of NSAIDs, ranging from 
dyspepsia to life-threatening gastrointestinal ulcerations [13, 14]. Metamizole, however, 
showed much less gastrointestinal toxicity, which is an argument against clinically relevant 
inhibition of COX-1, at least in the gastrointestinal tract [15-17]. Moreover, the 
cardiovascular effects associated with NSAIDs have recently gained increasing attention [14, 
18, 19]. The use of NSAIDs, especially the use of selective cyclooxygenase-2 (COX-2) 
inhibitors, is associated with an increased risk for myocardial infarction and death, 
particularly in patients with known cardiovascular disease [18]. So far, no cardiovascular risk 
has been reported for metamizole, supporting the absence of a clinically relevant COX-2 
inhibition [20]. 
Metamizole is a prodrug (see Figure 1). It reaches the systemic circulation after non-
enzymatic cleavage to 4-N-methylaminoantipyrine (4-MAA), which can be N-demethylated 
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by cytochrome P450 enzymes to 4-aminoantipyrine (4-AA). 4-AA can be N-formylated to 4-
N-formylaminoantipyrine or N-acetylated to 4-N-acetylaminoantipyrine (4-AAA). 
The pathomechanism of impaired renal perfusion associated with NSAIDs is well 
established. Vasodilatory prostaglandins such as prostacyclin are crucial to maintain renal 
perfusion in conditions with low intravascular pressure; inhibition of renal prostaglandin 
synthesis by NSAIDs can therefore impair renal perfusion. However, it is not entirely clear 
whether metamizole is a valuable alternative to NSAIDs in such situations because little is 
known about the effect of metamizole on renal function. Regarding renal complications in 
patients treated with metamizole, mainly case reports with acute kidney injury due to 
impaired renal perfusion or acute interstitial nephritis have been described in the literature 
[21-23]. The mechanisms proposed include impairment of prostaglandin synthesis by COX-
inhibition similar to NSAIDs for impaired renal perfusion and allergic reactions for interstitial 
nephritis [21]. In 1995, Farker and colleagues investigated the influence of metamizole and 
diclofenac on glomerular filtration and renal perfusion in healthy male subjects by measuring 
the creatinine and inulin clearances and the clearance of para-aminohippurate (PAH), 
respectively [1]. In their study, neither metamizole, nor diclofenac at therapeutic doses over 
3 days had an effect on GFR or renal plasma flow. Since diclofenac lacked an effect on these 
parameters also in other studies [24-28], it appears to be difficult to demonstrate the 
consequences of COX inhibition on renal function in healthy volunteers. Results from studies 
with naproxen were not consistent, but more studies showed a decrease in the GFR if 
measured using inulin clearance rather than estimated using creatinine clearance [29-31]. 
Taking into account the wide-spread use of metamizole in certain countries and the lack 
of conclusive data regarding its influence on renal function, the primary aim of the current 
study was to examine the effect of metamizole on inulin clearance, urinary excretion of 
sodium and potassium and urinary excretion of the stable prostacyclin-metabolite 6-keto-
prostaglandin   F1α   (6-keto-PGF1α)   in   comparison   with   the   non-specific COX-inhibitor 
naproxen in healthy, salt-depleted, male volunteers. A secondary aim was to obtain 
pharmacokinetic data for the four major metamizole metabolites and to correlate these data 
with pharmacodynamic effects. 
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Figure 1 Metabolism of metamizole into the four primary metabolites 
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Methods 
Materials 
Metamizole was administered as Novalgin® 500mg tablets (Sanofi-Aventis Suisse SA, 
Vernier, Switzerland) and naproxen as Naproxen-Mepha® Lactabs 500mg (Mepha Pharma 
AG, Basel, Switzerland). Inulin (Inutest® 25% ampules) was from Fresenius Medical Care AG 
(Oberdorf, Switzerland). D-Glucose/D-Fructose Test-Combination was from R-Biopharm AG 
(Darmstadt, Germany), glucose-oxidase from Aspergillus niger and invertase from baker's 
yeast (S. cerevisiae) were from Sigma-Aldrich (Buchs, Switzerland). Citric acid, sodium citrate, 
and hydrogen peroxide 30% were also purchased from Sigma-Aldrich (Buchs, Switzerland). 
Gradient grade water, methanol, isopropanol and formic acid of analysis grade (98-100%) 
for liquid chromatography were obtained from Merck (Darmstadt, Germany). Chloroform 
was from Carl Roth (Karlsruhe, Germany) and O-(2,3,4,5,6-pentafluorobenzyl)hydroxylamine 
hydrochloride (PFBHA) was from Sigma-Aldrich (Buchs, Switzerland). All reference 
compounds and internal standards for naproxen and metamizole quantification were 
products of Toronto research chemicals (Toronto, Canada). 6-keto  PGF1α,  6-keto  PGF1α-d4, 
and 2,3-dinor-6-keto-PGF1alpha were obtained from Cayman chemicals (Ann Arbor, 
Michigan, USA). Stock solutions of naproxen (10 mg/mL), 6-Keto  PGF1α-d4 (1 mg/mL) and 
the metamizole metabolites 4-methylaminoantipyrine (4-MAA; 10 mg/mL), 4-
aminoantipyrine (4-AA; 5 mg/mL), 4-formylaminoantipyrine (4-FAA; 5 mg/mL), and 4-
acetylaminoantipyrine (4-AAA; 5 mg/mL) were prepared in dimethyl sulfoxide (DMSO; 
Sigma-Aldrich, St. Louis, USA). The internal standards 2,3-Dinor 6-Keto  PGF1α-d9, 4-MAA-d3, 
4-AA-d3, and 4-AAA-d3, and naproxen-d3 were dissolved in DMSO to a final concentration of 
1 mg/mL.  
 
Study protocol 
This single-center, randomized, open-label, parallel-group study in healthy, male, salt-
depleted subjects was approved by the local ethics committee (Ethikkommission beider 
Basel) and the Swiss Agency for Therapeutic Products (Swissmedic) and was registered at 
ClinicalTrails.gov (NCT01995006). Before inclusion into the study, we obtained written 
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informed consent and performed a physical examination including routine laboratory tests 
of each subject. After inclusion, subjects were randomized into two treatment groups 
receiving either 1000 mg metamizole three times a day (n=8 subjects) or 500 mg naproxen 
twice a day for 7 days (day 1 to 7) (n=7 subjects). One week before the first study day 
(day ̵7), the subjects started a low sodium diet containing approximately 50 mmol sodium 
per day [32, 33]. The diet was maintained during the whole study period (until the last blood 
sampling on day 8). Lunch and dinner with reduced sodium content were provided at the 
University Hospital during the whole study period. For breakfast and snacks, we delivered 
written dietary instructions. Urinary sodium excretion was measured in 24-hour urine on 
days -4, 1, and 7. 
 
Determination of inulin clearance 
On day 1, after an overnight fast, a venous catheter was placed on each forearm. After 
the collection of baseline plasma samples, we started an inulin infusion at 125 mg/min for 20 
minutes followed by 28 mg/min for 400 minutes according to the instructions of the 
manufacturer. After an equilibration period of one hour, we collected a baseline urine 
sample for the inulin determination (t-1 to t0), before subjects ingested a single dose of either 
1000 mg metamizole or 500 mg naproxen (t0). We continued to collect hourly urine and 
plasma samples for the determination of the respective inulin concentrations for the next 
five hours (t5). The inulin clearance was calculated according the following formula: 
 
   𝑏𝑠 =   ට௦௜௭௘  (௖௠)∗௪௘௜௚௛௧(௞௚)ଷ଺଴଴  
where inulinurine is the urinary concentration of inulin, volumeurine the urinary volume, 
inulinplasma the inulin plasma concentration, time the collecting period, and bs the body 
surface. To ensure a minimal urinary flow of 2-3  mL/min   (according   to  the  manufacturer’s  
recommendation), we instructed the volunteers to drink 700 mL of water within the first 30 
min after the start of the inulin infusion, followed by additional 300 mL of water per hour 
until the end of the inulin infusion (t5).  
bstimeinulin
volumeinulinClearance
plasma
urineurine
inulin 
 73.1
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Plasma and urinary inulin concentrations were measured using an enzymatic method 
without deproteinization as described by Kuehnle and colleagues [34]. The assay was 
performed with half of the suggested volume of plasma or urine. Standard curves were 
linear in plasma (mean r2 0.9994, n=17) and in urine (mean r2 0.9991, n=12). For different 
concentration calibrators, the coefficients of variation for repetitive determinations were 
6.2-9.6% for plasma and 9.6-11.2% for urine. 
 
Determination of urinary sodium and potassium excretion and urinary excretion of 6-keto-
PGF1-alpha 
We measured sodium and potassium excretion in aliquots of hourly urine collections. 
Urinary potassium concentrations were analyzed using ion-specific electrodes at the central 
laboratory of the University Hospital Basel. Urinary sodium concentrations were analyzed at 
the environmental health and safety laboratory, Department of Environment and Energy 
Basel, using an inductively coupled plasma mass spectrometry (ICP-MS) method with a 
detection limit of 0.05mg/L. Concentrations of 6-keto-PGF1-alpha in urine were determined 
using an LC-MS/MS method at the laboratory of the division of clinical pharmacology and 
toxicology, University Hospital Basel. 
 
LC-MS/MS instrumentation 
Naproxen and metamizole analyses were performed on a Shimadzu HPLC system (Kyoto, 
Japan) coupled to an API 4000 tandem mass spectrometer (AB Sciex, Massachusetts, USA). 
6-keto-PGF1-alpha was analysed on a UPLC system from Shimadzu connected to an AB Sciex 
API 5500 tandem mass spectrometer. The HPLC system consisted of two LC-20AD pumps, 
two LC-20AD XR pumps, a CTO-20AC column oven, a DGU-20A5 degassing unit, a CBM-20A 
controller, and a CTC HTS PAL autosampler (Zwingen, Switzerland). The UPLC system had the 
same configuration except that four 30-AD pumps and a SIL-30AC autosampler were used. 
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Metamizole LC-MS/MS settings 
4-MAA, 4-AA, 4-FAA, and 4-AAA were separated on a pentafluorophenyl phase column 
(Luna 3 µ PFP 50x2.0 mm, Phenomenex, CA, USA) using water (A) and methanol (B) as 
mobile phases. Both mobile phases were supplemented with 0.1% (v/v) formic acid. The 
introduced samples (2 µL) were pre-column diluted via a t-piece with water 0.1% formic acid 
transported by pump C. The flow rate of pump C was thereby reduced from 0.3 to 0 ml/min 
within the first 0.5 minutes of each run. Pumps A and B initially were set at 0.1 ml/min and 
increased to 0.5 ml/min within the first 0.5 min. In the last 0.5 min of the run the flow rate 
was switched back to the initial conditions. The following mobile phase gradient program 
was used for separating the analytes: 0-0.25 min; 2% mobile B, 0.25-3.5 min; 2-55% mobile 
B, 3.51-4.5; 95% mobile B, 4.51-5.0 min; 2% mobile B. The HPLC stream was connected 
between minute 1 and 3 to the mass spectrometer otherwise to the liquid waste. The 
retention time of 4-MAA was 1.62 min, of 4-AA 1.74 min, of 4-FAA 2.43 min, and of 4-AAA 
2.5 min. Chromatographic separation was carried out at 43° C. 
All analytes were detected in the positive mode using electrospray ionization. The 
applied mass transitions and compound specific parameters are illustrated in the 
Supplemental Table 1. Mass spectrometer was running at an Ion source gas 1 of 50 l/min 
(N2), an Ion source gas 2 of 60 l/min (N2), a curtain gas of 10 l/min, a collision gas of 6 l/min, 
an ion spray voltage of 5500 V, and a source temperature of 600°C. Analyst software 1.6.1 
(AB Sciex, MA, USA) was used to operate the LC-MS/MS system. 
 
Naproxen LC-MS/MS settings 
Naproxen was eluted on a reversed phase core-shell C18 column (Kinetex 2.6 µm, 50x2.1 
mm; Phenomenex, CA, USA). Similar mobile phases were used as for the metamizole 
analysis. The flow rate was set to 0.5 ml/min at 45°C column oven temperature. The HPLC 
gradient program was as follows: 0-0.25 min; 40% mobile B, 0.25-1 min; 40-95% mobile B, 1-
2 min; 95% mobile B, 2.01-2.25 min; 40% mobile B. Naproxen eluted after 1.3 minutes 
runtime.  
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Naproxen and naproxen-d3 were detected in the negative ionization mode. Mass 
transition and compound specific settings of the two analytes are illustrated in the 
Supplemental Table 1. General settings of the mass spectrometer were similar to the 
metamizole analysis except that the ion spray voltage was set to -4500 V. 
 
Metamizole and naproxen quantification in plasma samples 
Calibration lines were prepared in drug free blank human plasma obtained from the local 
blood donation center (University Hospital Basel, Switzerland). Thereby, analyte stock 
solutions were serially diluted with DMSO and each dilution was mixed with blank plasma at 
a ratio of 1:100. Calibration ranges, which included 10-11 calibrators, were established from 
25-50’000  ng/mL  for  naproxen,  from  50-50’000  ng/mL  for  4-MAA, from 25-5000 ng/mL for 
4-FAA, and from 5-5000 ng/mL for 4-AA and 4-AAA.  A  correlation  coefficient  of  ≥0.99   (R2) 
was at least required. Quality control samples were prepared at low, medium, and high 
concentration levels. A mean accuracy of 85-115% (80-120% at the lower limit of 
quantification (LLOQ)) and a precision of 15% (LLOQ: 20%) was accepted in our study.  
Plasma aliquots of 50 µL were precipitated with 500 µL methanol containing the internal 
standards (4-AA-d3: 10 ng/mL, 4-AAA-d3: 50 ng/mL, 4-MAA-d3: 25 ng/mL, naproxen-d3: 
500ng/mL). Samples were mixed with a VX-2500 multi-tube vortexer (VWR, Dietikon, 
Switzerland) for about 1 min and centrifuged at 4000 rpm during 30 min (Eppendorf 5810R, 
Hamburg, Germany). 2 µL supernatant were injected into the LC-MS/MS system.  
 
6-keto PGF1α  LC-MS/MS settings 
Derivatization of the ketone group of 6-keto   PGF1α   using   (O-(2,3,4,5,6-
Pentafluorobenzyl)hydroxylamine hydrochloride resulted in the formation of two isomers. 
These isomers were separated on a Kinetex C18 column (2.6 µm, 50 x 2.1 mm, Phenomenex, 
CA, USA). Mobile phase A was a solution 5mM ammonium bicarbonate (Sigma-Aldrich, MO, 
USA) in water. Isopropanol was used for mobile B. The introduced samples (50 µL) were pre-
column diluted via a t-piece during the first 0.5 min of each run with mobile phase A (flow 
rate gradient of pump C: 0.35 to 0 mL/min). Flow rates of pumps A and B were increased 
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from 0.35 to 0.7 mL/min in the first 0.5 min of each run. In the last 0.5 min of the run the 
flow rate was switched back to the initial conditions. The following mobile phase B gradient 
program was used: 0-11 min; 2-23%, 11-12 min; 23-95%, 12-13 min; 95%, 13-13.5 min; 2%. 
HPLC and mass spectrometer were connected during minute 8 and 11.5 min of each run to 
monitor 2,3-dinor-6-keto-PGF1α   which   eluted   after   9.4   min   and   the   two   PFBHA-6-keto 
PGF1α  isomers,  which  had  a  retention  time  of  10.0  and  10.4  min,  respectively.  Column  oven  
temperature was set at 60°C.  
All analytes were detected in the negative mode using atmospheric pressure chemical 
ionization. The applied mass transitions and compound specific parameters are illustrated in 
the Supplemental Table 1. The mass spectrometer was running at an Ion source gas 1 of 45 
l/min (N2), an Ion source gas 2 of 60 l/min (N2), a curtain gas of 30 l/min, the collision gas 
was set on medium flow, an nebulizer current voltage of -4.5 V, and a source temperature of 
400°C. Analyst software 1.6.1 (AB Sciex, MA, USA) was used to operate the LC-MS/MS 
system. 
 
6-keto-PGF1α  quantification  in  urine  samples 
Calibration lines were prepared by spiking blank human urine with 6-keto  PGF1α-d4 (in 
DMSO) at a ratio of 1:1000. Ten calibrators from 10 to 2500 pg/mL were used to establish a 
calibration line. Linearity was sufficient   if  the  correlation  coefficient  was  ≥0.99  (R2). Quality 
control samples were prepared at low (75 pg/mL), medium (250 pg/mL), and high (750 
pg/mL) concentration levels. A mean accuracy of 85-115% and a precision of 15% was 
accepted in our study.  
We applied a modified liquid-liquid extraction technique as described by Sterz et al. [35]. 
Aliquots   of   2  mL   urine  were   used   for   analysis.   Before   extraction,   20   μl   of   acetic   acid  was  
added to each sample, followed by 8 mL of the IS (2,3-dinor-6-keto-PGF1α)   in a methanol-
chloroform (2:1 v/v) mixture. The samples were mixed during half an hour and incubated for 
another half an hour at room temperature. After adding chloroform and water (2.5 mL 
each), the samples were mixed during 10 minutes and afterwards centrifuged for 10 minutes 
at 2000 rpm. The chloroform phase was evaporated under a gentle stream of nitrogen at 
40°C with a Turbo Vap LV (Caliper Life Science, MA, USA). The residue was dissolved in a 200 
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μl   isopropanol-water-PFBHA solution (4:5:1, v/v) and incubated for 30 minutes at 60 °C for 
derivatization (Blatnik et al, 2010). 50 µL was injected into the LC-MS/MS system. Quantified 
concentrations of 6-keto-PGF1α   were   normalized   to   the   creatinine   concentrations   of   the  
urine samples to compensate for differences in urine dilutions. 
Pharmacokinetic Analysis 
Plasma samples for the pharmacokinetic evaluation were drawn before and at 1, 2, 3, 4, 
5, 8, 12, and 24 hours after drug administration. Starting on day 2, the full doses were given 
until day 7. On day 7, the PK measurements were repeated at the same time-points as on 
day 1. 
Plasma concentration data were analyzed using non-compartmental methods. Peak 
plasma concentrations (Cmax) and time to reach Cmax (Tmax) were directly obtained from 
observed concentration-time data. The terminal elimination rate constant   (λz) was 
determined by log-linear regression using at least three data points in the elimination phase. 
The area under the concentration-time curve (AUC) from zero to infinity after dosing (AUC0-
inf_obs) was estimated using the linear trapezoidal method and was extrapolated to infinity 
based on the last observed or predicted concentration. Additionally, partial area under 
concentration-time curve from 0 to 5 hours (AUC0-5h) was calculated for comparison of the 
two treatment days. The terminal elimination half-life  was  calculated  using  λz. Calculations 
were done using the PK Solver add-in (version 2.0) for Microsoft Excel [36].  
 
Statistical analysis 
Statistical analyses were performed using Microsoft Office Excel (Version 2010, 
Redmond, Washington, USA) and GraphPad PRISM (Version 6, La Jolla, California, USA). For 
variables with normally distributed numerical values, the arithmetic mean and standard 
deviation were calculated. For variables without normally distributed values, median and 
range were determined. Calculated inulin clearance and urinary sodium excretion values 
were parameterized by calculating an area under effect curve (AUEC) from time 0 to 5 hours. 
AUECs between the metamizole and the naproxen group were statistically compared using a 
Mann-Whitney-U-test whereas AUECs within a treatment group but of the different study 
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days were tested using a Wilcoxon-test. The course within a treatment group on one day 
was evaluated using a Friedman-test. Differences were considered as significant when 
p ≤ 0.05. 
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Results 
Fifteen subjects completed the study (mean age 24.3 years [range 18 to 29 years], mean 
BMI 23.2 kg/m2 [range 18.6 to 27.8 kg/m2]). Eight subjects received metamizole, 7 subjects 
received naproxen. Two subjects had to be excluded because of adverse reactions caused by 
inulin before the administration of the study drug. One of the excluded subjects developed 
an allergic reaction with bronchospasm (CTCAE grade 3) and the other subject suffered from 
vomiting after the start of the inulin infusion (CTCAE grade 1). The drugs were well tolerated, 
with only mild and no unexpected adverse events.  
Reduced dietary sodium intake was monitored by determination of urinary sodium 
excretion in 24 hour urine collections during the pre-study period (day -4) and at the start 
(day 2) and the end (day 8) of the treatment period. Median urinary sodium excretion was in 
the target range of less than 60-80 mmol/day on day -3 and day 2, but exceeded the target 
range at the end of the dosing period (Table 1).  
Table 1 Urinary sodium excretion in 24 hour urine samples 
Sodium excretion [mmol/day] 
median (range) 
Metamizole n=8 Naproxen n=7 
pre-study period (day-3) 52 (29-64) 43 (29-67) 
start of treatment (day 2)  53 (26-82) 52 (34-132) 
end of treatment (day 8) 85 (31-127) 104 (85-121) 
 
The concentration-time profiles of the four main metamizole metabolites after a single 
oral dose are shown in Figure 2 and the corresponding pharmacokinetic parameters are 
listed in Table 2. On day 7, subjects continued study drug intake and had two additional 
metamizole doses 5h and 12h or one additional naproxen dose 12h after the morning dose. 
Therefore, no 24 hour steady-state PK profile could be obtained after the last study drug 
dose. The first metabolite formed, 4-MAA, reached the highest plasma concentration of all 
metabolites, both after single and multiple doses. After single dose, the Cmax values for 4-AA, 
4-AAA and 4-FAA were 10 to 20 times lower than for 4-MAA. After multiple dose, the 
differences in the Cmax values were less pronounced because the half-lives of 4-AA, 4-AAA 
and 4-FAA are longer than for 4-MAA. 
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The concentration-time profiles of naproxen are shown in Supplemental Figure 1 and the 
corresponding pharmacokinetic data are listed in Supplemental Table 2. After application of 
a single dose, the half-life of naproxen was in the range of 18 hours, corresponding to 
published values [37]. After repetitive dosing, a slight increase in Cmax and AUC0-12h compared 
to single dose was observed. 
Table 2 Pharmacokinetic parameters after a single oral dose of 1000 mg metamizole (n=8) on day 1 and after multiple doses 
(1000 mg TID) on day 7 
 4-MAA 4-AA 4-AAA 4-FAA 
Day 1     
T1/2 [h] 3.7 (2.8-4.4) 5.8 (4.0-12.4) --- 16.0 (8.9-27) 
Tmax [h] 1(1-2) 5 (3-5) 12 (8-24) 8 (5-12) 
Cmax [mg/L] 14.9 (11.9-18.5) 1.2 (0.6-2.5) 1.6 (0.8-2.5) 1.9 (1.4-2.3) 
AUC0-24h [mg/L x h] 105 (67-128) 15 (7-31) 30 (15-47) 34 (27-40) 
AUC0-5h [mg/L x h] 58 (48-70) 4.3 (2.3-8.8) 2.9 (1.0-5.2) 5.9 (4.2-7.6) 
     
Day 7     
Cmax [mg/L] 21.2 (15.7-24.8) 3.0 (1.1-8.9) 8.3 (2.0-11.3) 3.5 (2.0-4.8) 
Cmax ratio MD/SD 1.35 2.22 4.85 1.77 
AUC0-5h [mg/L x h] 82.6 (55.1-106) 13.9 (4.8-42.4) 39.1 (9.2-53.9) 16.3 (8.7-22.0) 
AUC0-5h ratio MD/SD 1.42 3.24 13.35 2.77 
Values are listed as median and ranges. AUC0-24h partial area under concentration-time curve from 0 to 24 
hours, AUC0-5h partial area under concentration-time curve from 0 to 5 hours (adapted to dosing interval, 
before second daily dose), Cmax maximum plasma concentration, MD multiple dose, SD single dose, T1/2 half-life, 
TID three times per day, Tmax time to maximum plasma concentration 
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Figure 2 Mean plasma concentration of the four main metabolites of metamizole vs. time in healthy volunteers (n= 8) 
following a single oral dose of 1000 mg (A) and after seven days of continuous intake of 1000 mg three times per day (B). 
*oral drug intake 
 
As shown in Figure 3A and B, the GFR (as reflected by the inulin clearance) increased 
relative to baseline in both the naproxen and the metamizole group after single and 
repetitive dosing. A statistical comparison between the metamizole and naproxen group did 
not reach statistical significance. Likewise, no significance was observed within a medication 
81 
 
group when day 1 and day 7 were compared. The mean GFR values at baseline were 
74.5 mL/min and 82 mL/min in the metamizole and naproxen group, respectively. 
The urinary fractional sodium excretion showed a trend to higher values after single dose 
treatment with metamizole and with naproxen, without reaching statistical significance 
between metamizole and naproxen or between the two study days (Fig. 3C). After 7 days of 
treatment with naproxen, a trend to decreased renal sodium excretion was observed, 
without reaching statistical significance (Fig. 3D AUEC naproxen versus metamizole, p=0.07; 
AUEC naproxen day 1 versus day 7, p=0.81). The highest reduction of the fractional sodium 
excretion was observed 3 hours after naproxen dosing on day 7, (Fig. 3D, p=0.006 compared 
to baseline). 
As shown in Figure 3E and 3F, the effect of metamizole and naproxen on renal excretion 
of potassium was minimal and did not reach statistical significance between metamizole and 
naproxen. Detailed data of the urinary volumes, urinary sodium excretion, and urinary 
creatinine concentrations for the different one hour collection intervals are listed in 
Supplemental Tables 3 to 5. 
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Figure 3 Mean changes in glomerular filtration rate (GFR) (A +B), fractional urinary sodium excretion (UNa) (C +D), and 
fractional urinary potassium excretion (UK) (E + F) measured after a single oral dose of 1000 mg metamizole (solid line) or 
500 mg naproxen (dashed line) on day 1 (left panel, A, C, E) and in a steady state situation on day 7 (right panel, B, D, F). 
Data are presented as mean values ± SEM 
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The fractional excretion of urinary 6-keto-PGF1α decreased under naproxen as well as 
under metamizole. Figures 4A and 4B summarize the data obtained after a single dose (day 
1) and at steady state (day 7). The baseline urinary 6-keto-PGF1α concentrations on day 1 at 
time 0 were quantifiable for all subjects for both treatments. After a single dose of 
metamizole, the 6-keto-PGF1α excretion started to decrease at 2 hours and remained low up 
the 5 hours. A similar picture was seen after a single dose of naproxen. At steady state 
conditions (day 7), the value before ingestion of the morning dose (time 0h) was lower than 
the corresponding value at day 1, indicating a long-lasting effect of both treatments on renal 
excretion of 6-keto-PGF1α. Since urinary excretion of 6-keto-PGF1α was already low at the 
beginning (time 0h) of day 7, ingestion of 500 mg naproxen or 1000 mg metamizole had 
almost no observable effect on quantifiable 6-keto-PGF1α over the observation period of 5 
hours. In many cases concentrations of 6-keto-PGF1α dropped to levels below the limit of 
quantification (LLOQ, 8 pg/mL) after ingestion of metamizole or naproxen. Since values 
below LLOQ were set as LLOQ, the averages shown in Figure 4A and 4B overestimate the real 
values. Individual 6-keto-PGF1α excretion profiles combined with urine creatinine 
concentrations are shown in Supplemental Figure 2A and 2B. For the majority of the 
subjects, the urine creatinine concentrations in the 2- to 5-hour fractions were comparable 
to the baseline fraction, indicating that the observed decrease of 6-keto-PGF1α 
concentrations after metamizole or naproxen was not caused by urine dilution.  
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Figure 4 Mean urinary 6-keto-PGF1α excretion measured after a single oral dose of 1000 mg metamizole (A) or 500 mg 
naproxen (B) on day 1 and in a steady state situation on day 7 
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Discussion 
In this study we investigated the pharmacokinetics of 4 metamizole metabolites and the 
effect of single and repetitive doses of metamizole on renal function compared to naproxen 
in salt depleted healthy human volunteers. After a single dose, both metamizole and 
naproxen increased inulin clearance and renal sodium excretion and decreased renal 6-keto-
PGF1α excretion. After 7 days of continuous treatment, both metamizole and naproxen 
increased inulin clearance and decreased renal excretion of 6-keto-PGF1α. Metamizole did 
not affect renal excretion of sodium, whereas naproxen was associated with a decrease. 
None of the treatments had a relevant effect on potassium excretion after single or repeated 
dosing.  
 
Pharmacokinetics 
The observed pharmacokinetic data of metamizole are in line with previously published 
values. The main metabolite 4-MAA showed a median half-life of 3.7 hours, which is 
comparable to published values [38, 39]. The observed half-life for the other active main 
metabolite 4-AA was between reported values for slow and rapid N-acetylators (rapid 
acetylators 3.8 hours, slow acetylators 5.5 hours [38]). The values for Tmax observed in the 
current study for 4-MAA and 4-AA were between 1 and 2 hours and between 3 and 5 hours, 
respectively, as reported previously for 4-MAA (1.2-1.9 hours) and for 4-AA (3.2-6.7 hours) 
[39]. The Cmax of 4-MAA observed in the current study was in the higher range (14.9 mg/L in 
current study compared to 9.7-17.3 mg/L) and the AUC0-inf was higher than previously 
published values (107 mg/L x h in the current study compared to 64.5-95.1 mg/L x h [39]). 
The ratios of Cmax and AUC0-5 of repetitive to single doses were clearly larger than 1, 
indicating accumulation of metabolites. Accumulation could be expected taking into account 
the half-lives (3.7, 5.8 and 16.0 h for 4-MAA, 4-AA, 4-FAA, respectively) in relation to the 
dosing interval of 8 hours. Considering 4-MAA and 4-AA, which are both regarded as 
pharmacologically active metabolites [39], 4-MAA reached approximately 10 times and 7 
times higher values for Cmax and AUC compared to 4-AA after single and repetitive dosing, 
respectively. It can therefore be assumed that the analgesic activity of metamizole is 
primarily associated with 4-MAA after both single and repetitive dosing. Regarding toxicity, 
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whose mechanisms are currently not well established, the other metabolites may also 
contribute. 
Previously published pharmacokinetic data have been analyzed using HPLC methods, 
whereas our measurements were performed using a more specific LC-MS/MS method. Since 
the data agree well with each other, HPLC methods appear to be specific enough for this 
analysis. There are no newer studies dealing with pharmacokinetic properties of the 
metabolites of metamizole. Studies have been published, however, trying to find genetic and 
non-genetic factors influencing the pharmacokinetic profile of metamizole metabolites, 
which may influence both the pharmacological action of metamizole and also its toxicity. 
[40, 41].  
 
Effect on renal function 
The low absolute values for inulin clearance suggest a methodological bias in our 
assessment. Compared to the estimated baseline GFR using the CKD-EPI equation, the 
average inulin clearance was approximately 20 mL/min lower. A reason for the low baseline 
values could be an incomplete distribution of inulin after the 1 hour equilibration period 
with changing plasma concentrations and renal excretions. Since the formula used to 
calculate inulin clearances presumes stable plasma levels over the entire observation 
interval, the calculated clearances may be biased. Another reason for this observation could 
be an incomplete voiding of the bladder by the subjects. On the other hand, it has previously 
been reported that measured creatinine clearances can exceed corresponding inulin 
clearances, possibly due to additional tubular creatinine secretion. In one study, the ratio of 
measured creatinine clearance to inulin clearance varied between 1.14 and 2.27, which is 
similar to our findings [42]. 
Surprisingly, the inulin clearance numerically increased with time in both treatment 
groups after drug intake, suggesting an increase rather than the expected decrease in GFR. 
We interpreted the increase in inulin clearance as a consequence of the water load applied 
in order to maintain a sufficient urinary flow. Interestingly, although the extent of the water 
load was the same on both study days (day 1 and day 7), the increase in inulin clearance was 
less pronounced after repetitive compared to single dosing, in particular for naproxen. In 
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comparison, in a previous clinical study with a comparable study design, there was also no 
decrease in GFR after single dose naproxen, but a fall in the GFR in the steady state situation 
[33]. Since naproxen, which was used as a positive control, was not associated with a 
measurable effect on inulin clearance in the current study, it is difficult to evaluate the effect 
of metamizole on GFR. Under the conditions of our experiment, metamizole did not affect 
inulin clearance both after a single and during repetitive dosing. 
The results for urinary sodium excretion are similar to those obtained for inulin 
clearance. After a single dose, both metamizole and naproxen increased sodium excretion, 
explained best by the water load applied to the study subjects. After repetitive dosing at 
day 7, however, the sodium excretion was not affected by metamizole but decreased in the 
subjects treated with naproxen (Figure 3C and 3C). In a previous study, the sodium clearance 
decreased already after a single dose of naproxen [33]. A possible reason for this difference 
could be the more pronounced salt depletion in the previous compared to the current study, 
as suggested by the lower sodium excretion at baseline before drug application (26.1 to 36.7 
mmol/day vs. 43 to 52 mmol/day in the current study) despite aiming at an identical sodium 
ingestion of 50 mmol/day. 
Regarding the urinary 6-keto-PGF1α excretion, we observed the expected inhibition in 
the naproxen group (Figure 4). The inhibition started at 2 h after ingestion, which 
corresponds to the Tmax of naproxen. Since the values were below the detection limit in most 
subjects at the morning of day 7 before drug ingestion, 6-keto-PGF1α excretion was still 
impaired in most subjects after the doing interval of 12 h for naproxen. Interestingly, 
metamizole also inhibited renal excretion of 6-keto-PGF1α (Figure 4). After a single dose, 
maximal inhibition was reached at 2 h, correlating with Tmax for 4-MAA, but not for the other 
metabolites. At day 7, before ingesting metamizole morning dose, 6-keto-PGF1α was 
detectable in 4 of subjects, but the average appeared to be slightly lower than at baseline. 
Regarding Tmax and half-life of the active metamizole metabolites, 4-MAA and 4-AA, these 
results suggest that the initial decrease in renal 6-keto-PGF1α excretion has mainly been 
caused by 4-MAA, but that 8 h after dosing 4-AA may also have contributed to the effect.  
A decrease in renal prostaglandin excretion after metamizole intake has already been 
shown in a study with healthy volunteers [43] and in a study in patients with liver cirrhosis 
[2]. Clinical experience suggests a better renal tolerability of metamizole compared to 
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NSAIDs. The pathomechanism of decreased glomerular filtration associated with NSAIDs is 
known to be based on the inhibition of renal prostaglandin synthesis. The vasodilatory 
prostacyclin is important to maintain sufficient renal perfusion in conditions with low 
intravascular pressure. Since our subjects may not have reached a sufficient extent of 
sodium depletion leading to a low intravascular pressure situation (see limitation section), 
renal prostaglandin synthesis may not have been critical to maintain renal perfusion in our 
subjects. This could be an explanation why we did not observe a significant effect on inulin 
clearance and sodium excretion in the naproxen group. Another possible explanation for the 
better renal tolerability of metamizole despite the inhibition of vasodilatory renal 
prostaglandin synthesis could be a direct vasodilatory effect of metamizole, counteracting 
reduced renal availability of vasodilatory prostacyclin. Such a vasodilatory effect of 
metamizole has been described before in animal models for vasospasm [44, 45] 
In 14 patients with liver cirrhosis (50% with ascites, Child-Pugh score 7.0 ± 1.5), 
metamizole did not reduce renal function when used for short time periods (up to 72h) [2]. 
Since patients with liver cirrhosis are at high risk for renal complications after prostaglandin 
synthesis inhibition [46, 47], these results support the assumption of a better renal 
tolerability of metamizole compared to NSAIDs in patients with low intravascular filling 
pressures. The current study, which shows a similar inhibition of renal 6-keto-PGF1α 
excretion for metamizole and for naproxen suggests that renal excretion of 6-keto-PGF1α 
may not be the ideal marker to differentiate between the renal adverse effects of NSAIDs 
and metamizole. In this situation, measurement of the renal plasma flow would probably 
allow a better differentiation of the net effect of metamizole on renal vascular tone 
compared to NSAIDs. 
 
Limitations 
The most important limitation of the current study is the lack of effect of naproxen which 
was used as positive control on inulin clearance. Based on a previous report [33], the 
expected effect of naproxen on GFR was a reduction of approximately 20% after seven 
treatment days. The compliance with the low-sodium diet is most probably a crucial factor 
to render healthy subjects vulnerable for the renal effects of NSAIDs. Measurement of 
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sodium excretion in 24 hour urine collections showed that the subjects were compliant at 
the beginning but not at the end of the repeated dosing period (Table 1). This could be the 
reason for the lacking effect of naproxen on inulin clearance and sodium excretion during 
repetitive dosing at day 7. A second weakness of study is the small number of subjects 
included, which was chosen based on practical considerations. A third weakness is the lack 
of a placebo group which would have helped to demonstrate the effect of the water load on 
inulin clearance and renal sodium excretion. 
 
Conclusions 
Metamizole inhibits renal excretion of the prostacyclin metabolite 6-keto-PGF1α  similar  
to naproxen, suggesting that metamizole inhibits renal prostaglandin synthesis. Despite 
inhibition of renal 6-keto-PGF1α   excretion,  metamizole   had   no   significant   effect   on   inulin  
clearance or renal sodium excretion in healthy, moderately sodium-depleted subjects, 
whereas naproxen decreased sodium excretion. Renal tolerability of metamizole in patients 
at risk might be explained by a direct vasodilatory effect of metamizole counteracting 
reduced renal availability of vasodilatory prostacyclin. Further studies in more susceptible 
individuals, looking also at renal plasma flow have to be conducted to evaluate differences in 
the effects on renal function between metamizole and NSAIDs that would explain the better 
renal tolerability of metamizole observed in the clinical setting. 
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3.4.1. Supplementary material: Effect of metamizole (dipyrone) on renal function in 
salt-depleted healthy subjects 
Supplemental Table 1 Mass transitions and compound specific settings 
ID Q1 Mass (Da) Q3 Mass (Da) Time (msec) DP (V) CE (V) CXP (V) EP (V) 
4-AA 204.2 56.2 30 71 39 8 10 
4-AA-d3 207.2 59.1 30 46 39 10 10 
4-AAA 246.2 83.1 30 46 43 14 10 
4-AAA-d3 249.2 84.1 30 61 43 6 10 
4-FAA 232.2 204.1 30 46 19 12 10 
4-MAA 218.2 56.1 30 31 16 10 10 
4-MAA-d3 221.2 56.1 30 46 37 8 10 
Naproxen 229.1 168.8 50 -40 -36 -15 -10 
Naproxen-d3 232.1 170.8 50 -45 -40 -9 -10 
6-Keto  PGF1α 564.1 306.1 100 -155 -36 -21 -10 
6-Keto  PGF1α-d4 568.1 310.1 100 -155 -36 -21 -10 
2,3-Dinor 6-Keto  PGF1α-d9 545.2 259.0 100 -210 -28 -17 -10 
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Supplemental Table 2 Pharmacokinetic parameters after a single oral dose of 500 mg naproxen (n=7) on day 1 and after 
multiple doses (500 mg BID) on day 7 
 Naproxen 
Day 1  
T1/2 [h] 18.4 (12.8-21.8) 
Tmax [h] 2(2-5) 
Cmax [µg/mL] 63.2 (51.7-76.0) 
AUC0-inf_obs [µg/mL *h] 1293 (889-1528) 
AUC0-12h [µg/mL *h] 497 (398-560) 
Day 7  
Tmax [h] 2 (1-3) 
Cmax [µg/mL] 85.7 (67-101) 
Cmax ratio MD/SD 1.37 
AUC0-12h [µg/mL *h] 754 (572-817) 
AUC0-12h ratio MD/SD 1.52 
Values are listed as median and ranges. AUC0-inf_obs area under the concentration-time curve from zero to 
infinity extrapolated based on the last observed or predicted concentration, AUC0-12h partial area under 
concentration-time curve from 0 to 12 hours, Cmax maximum plasma concentration, MD multiple dose, SD 
single dose, T1/2 half-life, BID twice daily, Tmax time to maximum plasma concentration 
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Supplemental Table 3 Median sodium excretion (hourly intervals) of the two study days 
Sodium excretion [mmol/L], median (range) Metamizole n=8 Naproxen n=7 
Day 1  Baseline (t-1 to t0) 3 (2-8) 5 (2-35) 
 1h (t0-t1) 3 (2-8) 5 (2-19) 
 2h (t1-t2) 3 (1-8) 3 (1-17) 
 3h (t2-t3) 4 (1-8) 3 (1-16) 
 4h (t3-t4) 4 (1-10) 3 (0-18) 
 5h (t4-t5) 5 (2-10) 5 (1-18) 
Day 7 Baseline (t-1 to t0) 5 (4-31) 10 (4-13) 
 1h (t0-t1) 4 (5-13) 9 (4-15) 
 2h (t1-t2) 5 (2-18) 8 (3-12) 
 3h (t2-t3) 9 (5-25) 10 (5-19) 
 4h (t3-t4) 8 (5-63) 13 (7-21) 
 5h (t4-t5) 9 (6-18) 15 (6-25) 
 
Supplemental Table 4 Median urinary volume (hourly intervals) of the two study days 
Urinary volume [mL/h], median (range) Metamizole n=8 Naproxen n=7 
Day 1  Baseline (t-1 to t0) 310 (75-520) 590 (40-700) 
 1h (t0-t1) 435 (260-720) 520 (270-660) 
 2h (t1-t2) 420 (210-550) 410 (210-480) 
 3h (t2-t3) 320 (240-720) 350 (275-490) 
 4h (t3-t4) 390 (210-620) 325 (240-440) 
 5h (t4-t5) 380 (140-560) 320 (120-560) 
Day 7 Baseline (t-1 to t0) 400 (60-610) 530 (370-680) 
 1h (t0-t1) 440 (220-630) 550 (370-720) 
 2h (t1-t2) 425 (80-760) 480 (260-720) 
 3h (t2-t3) 350 (55-640) 360 (260-440) 
 4h (t3-t4) 365 (42-560) 410 (315-460) 
 5h (t4-t5) 380 (210-600) 365 (240-580) 
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Supplemental Table 5 Median urinary creatinine concentration (hourly intervals) of the two study days 
Urinary creatinine concentration [µmol/l], median (range) Metamizole n=8 Naproxen n=7 
Day 1  Baseline (t-1 to t0) 2004 (1188-5525) 1109 (617-10691) 
 1h (t0-t1) 1704 (631-2381) 1019 (714-2000) 
 2h (t1-t2) 1563 (743-2664) 1358 (1029-2516) 
 3h (t2-t3) 1633 (1070-2624) 1397 (1140-2083) 
 4h (t3-t4) 1697 (970-2159) 1575 (1045-1947) 
 5h (t4-t5) 1770 (1023-2243) 1604 (798-4255) 
Day 7 Baseline (t-1 to t0) 1426 (942-8591) 1216 (634-1724) 
 1h (t0-t1) 1309 (719-2335) 1146 (269-1622) 
 2h (t1-t2) 1352 (1149-6699) 1296 (703-1793) 
 3h (t2-t3) 1415 (1214-8413) 1606 (781-2444) 
 4h (t3-t4) 1589 (1017-11260) 1532 (1179-1770) 
 5h (t4-t5) 1634 (1025-3900) 1384 (317-2495) 
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Supplemental Figure 1 Mean plasma concentration of naproxen vs. time in healthy volunteers (n= 7) following a single oral 
dose of 500 mg (A) and after seven days of continuous intake of 500 mg twice a day (B). *oral drug intake 
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Supplemental Figure 2A Single profiles of urinary 6-keto-PGF1α  excretion  (closed  circles)  corrected  to  the  urinary  creatinine  
concentration (open squares) in healthy salt-depleted volunteers (n= 8) following a single oral dose of 1000 mg metamizole 
(Day 1) and after seven days of continuous intake of 1000 mg three times a day (Day 7). * symbol for concentration below 
the quantification limit 
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Supplemental Figure 2B Single profiles of urinary 6-keto-PGF1α  excretion  (closed  circles)  corrected  to  the  urinary  creatinine  
concentration (open squares) in healthy salt-depleted volunteers (n= 7) following a single oral dose of 500 mg (Day 1) 
naproxen and after seven days of continuous intake of 500 mg twice a day (Day 7). * symbol for concentration below the 
quantification limit 
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4. Discussion – Conclusion – Outlook  
4.1. Discussion 
4.1.1. Pharmacovigilance data analysis and case-control study: What is new? 
Clinical relevance of our findings 
In both the data from the pharmacovigilance analysis and the results of the case-control 
study, the large number of patients developed neutropenia or agranulocytosis within 1-7 
days after starting metamizole was striking (52% of the international dataset in the 
pharmacovigilance study and between one to two thirds in the post-OP and non-post-OP 
cases). In addition, the data showed that most reactions occurred within the first two 
months of therapy (>90%). This is of great importance regarding patient monitoring after 
starting metamizole. Especially during the first weeks, the physicians and patients should be 
vigilant for symptoms of myelotoxicity. On the other hand, patients, who have tolerated 
metamizole well over a long period (>2 months), have a low (although not negligible) risk of 
reacting with hematotoxicity in the future. 
The provided sale figures of all Swiss metamizole preparations confirmed that the use of 
metamizole has increased over the last years in Switzerland. The corresponding increase in 
reporting rate of fatalities due to metamizole-induced white blood cell disorders 
demonstrates the severity of this adverse reaction, despite broad-spectrum antibiotics and 
G-CSF as therapeutic options. Additionally, the sale figures allowed us to estimate a minimal 
incidence rate (0.46-1.63 per million person-days) which was in the range of the IAAA study 
[4]. Assuming underreporting, the real incidence must be higher. Our data, however, are 
nearer to the data from studies that have found rare incidences. Most probably, the truth 
lies somewhere in-between and is likely to be population-specific.  
The analysis of the seven reported fatal cases which occurred between 1991 and 2012 in 
Switzerland confirmed the previously described poor prognostic factors namely age >65 
years, septicemia and/or shock, and neutrophil count below 0.1G/L [54]. Additionally, we 
identified female sex and co-treatment with methotrexate as potential risk factors for a fatal 
outcome. Of course, as soon as patients have a myelotoxic co-medication, the effect of the 
two treatments on the adverse event cannot be kept apart. In our case-control study, the 
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non-post-operative case group had significantly more concomitant treatments with 
cytostatic agents compared to the non-post-operative controls. On the other hand, we did 
not see this in the post-operative comparison group. We know that metamizole is prescribed 
as an analgesic for oncological patients. Co-treatment with cytostatic agents is therefore not 
uncommon. But since an additive effect cannot be ruled out, especially concomitant 
methotrexate (four of seven fatal cases between 1991 and 2012), also at an 
immunosuppressive dose, should be used with caution. 
The female predominance for fatalities can partially be explained by the fact that more 
women suffer from autoimmune disease and therefore are treated with methotrexate. But 
in general, more cases of female patients with metamizole-induced white blood cell 
disorders are reported, both in the pharmacovigilance analysis as well as in the characterized 
cases managed at the University Hospital Basel. Final conclusions about female sex as a risk 
factor can only be drawn with sex-specific exposure data. Since we used a sex-matched 
design in the case-control study, this question cannot be answered with this study. However, 
The larger number of affected women might be explained by the higher exposure of females 
to analgesics [99]. 
The same problem arises regarding age as risk factor. The age-matched design of the 
post-operative comparison groups did not allow evaluation of age as a risk factor. The non-
post-operative comparison group was not age-matched. The age of the control group was 
significantly higher. Since these control patients were selected as long-term analgesic users, 
the fact that they were older can be seen as a selection bias. The fact that more cases 
involving older people are reported in many studies (also in our pharmacovigilance study), 
might be explained by a higher exposure of old patients to analgesics (analogous to the 
gender-question). The characterization of all the collected cases, however, clearly showed 
that patients from every age group can be affected. 
The fact that the adverse events mostly occur under a therapeutic dose and the mean 
daily doses for the non-post-operative comparison group did not differ significantly, is a hint 
against dose-dependent toxicity. Furthermore, overdoses are not usually accompanied by a 
fall of neutrophil granulocytes [90]. Our data do confirm this observation. 
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The toxicity seems to be associated with the presence of immunological and/or 
metabolic susceptibility factors in affected patients. The analysis of our case-control study 
showed a remarkably large number of patients with a positive allergy history among the 
post-operative cases. However, there was no statistically significant difference in the non-
post-operative comparison group. Since the source of the post-operative comparison groups 
was identical (electronic medical reports from the hospital) but different for the non-post-
operative comparison groups (electronic medical reports from the hospital and medical 
reports of general practitioners), the post-operative comparison was probably more 
homogenous and therefore more accurate. Nevertheless, it is possible that patients with a 
predisposition to allergic reactions have a susceptibility factor that makes them vulnerable 
to developing leucopenia under metamizole.  
Another potential risk factor that we identified in our case-control study was an 
underlying hepatitis C infection. The higher prevalence of an underlying hepatitis C infection 
in the case group fits to the previously made observation, that patients with viral infections 
including HIV, hepatitis C, EBV, HSV, HHV and CMV show an increased risk of developing 
adverse drug reactions [100-103]. The mechanisms behind this observation are not entirely 
clear, but could be caused by a combination of impaired immune tolerance, increased 
antigenicity and/or altered drug metabolism [93]. As an example for the altered drug 
metabolism, it is known that asymptomatic carriers of hepatitis B with normal liver function 
tests were found to have impaired clearance of metamizole via oxidative pathways 
compared to healthy controls, leading to increased exposure of the 4-
methylaminoantipyrine metabolite (carriers and controls all had slow acetylator phenotype) 
[104]. Finally it must also be considered, that patients with hepatitis C could develop 
myelotoxicity due to the hepatitis C infection itself [105-107]. 
In the case-control study, four of the in total 57 cases had previous leucopenic episodes 
in their medical history, whereas no patients in the control group were known to have a 
history of leucopenia. In two cases, the likeliest cause for the blood cell disorder was liver 
cirrhosis due to hepatitis C infection (for example due to hypersplenism-induced cytopenias 
[107]), thus another potential identified risk factor. In the other cases, the disorder was of 
unknown origin. The absolute number of cases is small and metamizole as a cause of the 
leucopenia can be questioned as these patients may have developed the disorder without 
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metamizole. However, there remains a possibility that these patients are more vulnerable. 
Therefore, metamizole should be used with caution in patients who have had pervious 
leucopenic episodes. 
 
4.1.2. Pharmacovigilance data analysis and case-control study: Methodological 
problems and limitations 
In both the pharmacovigilance data analysis and the retrospective case-control study, the 
problems of missing data and heterogeneity of documentation policies must be considered. 
The international pharmacovigilance dataset enabled the characterization of a large case 
collective. But without a control group, some questions cannot be answered (for example 
age or sex as risk factors). Therefore, we decided to perform a case-control study. But the 
question of how to identify the correct controls was a challenge. The first approach was to 
focus on a minimal continuous treatment duration of at least 28 days to ensure that control 
patients truly did not develop leucopenia. Since we did not find such long-term metamizole 
users in the hospital setting, we sought them in the outpatient settings. As a consequence, 
the control group largely consisted of older patients with chronic pain disorders. Since this 
patient collective differed strongly from the case group (mostly post-operative patients), we 
decided to split our cases in post-operative and non-post-operative cases and to collect an 
additional control group for the post-operative cases. These control patients were age-, sex- 
and ward matched to cases for the analysis. The disadvantage of this design is, however, the 
loss of ability to evaluate the effect of the matched factors. To further improve the study 
quality, a prospective design would be beneficial. But since the incidence of the adverse 
effect is low, the study period would have to be extremely long. 
The potential risk factors identified in the case-control study are based on a relatively 
small number of subjects. Additionally, our inclusion criteria were less restrictive than in 
other studies. As an example, Huber et al only included cases with a neutrophil count of less 
than 0.5 x 109/L, normal counts in other blood cell types, and excluded patients with 
concomitant cytostatic treatments [14]. Our approach included patients with a fall in 
leucocyte count below 3.5 x 109/L and did not exclude patients with additional abnormalities 
in other blood cell counts. Additionally, we also included patients with concomitant 
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cytostatics, if the blood counts were normal before starting metamizole. The causality of 
metamizole as the cause for the adverse drug reaction was assessed using the Naranjo Score 
[108]. The relatively open inclusion criteria make the results more disputable since the 
effects of several influences cannot be kept completely apart. But it allowed the assessment 
of potential additive effects and allowed also to study milder courses of the adverse drug 
reaction. 
 
4.1.3. Clinical study about renal safety of metamizole: What is new? Clinical 
relevance of our findings 
Regarding the supposed better renal tolerability of metamizole compared to 
conventional NSAIDs, data from our clinical study did not deliver finally answers to support 
this assumption. Nevertheless, the study delivered interesting results. Especially the fact, 
that metamizole seems to inhibit synthesis of renal prostacyclin to a similar degree as 
naproxen, was unexpected. However, two other studies have also observed this inhibition in 
healthy subjects and in patients with liver cirrhosis [109, 110]. Since patients with liver 
cirrhosis are at increased risk for renal complications after prostaglandin synthesis inhibition 
[111, 112], these results support the assumption of a better renal tolerability of metamizole 
in patients at risk compared to NSAIDs. The current study, which shows a comparable 
inhibition of renal 6-keto-PGF1α excretion for metamizole and for naproxen suggests that 
renal excretion of 6-keto-PGF1α may not be the ideal marker to differentiate between the 
renal adverse effects of NSAIDs and metamizole. Renal tolerability of metamizole in patients 
at risk might be explained by a direct vasodilatory effect of metamizole counteracting 
reduced renal availability of vasodilatory prostacyclin. Such a vasodilatory effect of 
metamizole has been described before in animal models for vasospasm [113, 114]. Further 
studies in more susceptible individuals, looking also at renal plasma flow have to be 
conducted to evaluate differences in the effects on renal function between metamizole and 
NSAIDs that would explain the better renal tolerability of metamizole observed in the clinical 
setting. 
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4.1.4. Clinical Study about renal safety of metamizole: Methodological problems 
and limitations 
The most important limitation of the current study is the lack of effect of naproxen (our 
positive control) on inulin clearance. There are several possible reasons for this observation, 
but the level of the salt-depletion seems to play a key role. Due to the only modest reduction 
in sodium intake during the course of the study, renal prostaglandin synthesis may not have 
been critical to maintain renal perfusion in our subjects. Although all subjects reached the 
target values (<60-80 mmol urinary sodium per day) before the first study day, urinary 
sodium excretion increased during the course of the study, indicating failing compliance with 
the dietary restriction. As a consequence, for another study, we would change several diet 
settings to render study participants more susceptible to COX inhibition. First of all, the 
compliance should be checked more often. Further, the duration of the diet could be 
shortened. The run-in time could be reduced to three or four days (instead of one week) 
with a single dose of a loop diuretic to boost initial sodium depletion. The allowed daily 
sodium intake should also be reduced to about 10 mmol per day. Preferably, the subjects 
should be in-house to ensure controlled intake also of breakfast and in-between meals. 
Another important point we would change is the equilibration time of the inulin infusion. 
The duration should be increased to two hours before start of the baseline collection 
(instead of one as suggested in the manufacturer’s   recommendation) to ensure that the 
inulin reaches stable concentrations in the plasma. This is necessary for the proper use of 
the traditional formula used to estimate inulin clearance. To avoid urinary samples and 
therefore incomplete bladder voiding, a single-shot inulin method could be used as well, 
based on a computer-based two-compartment model. This would also solve the questions 
concerning the appropriate equilibration time of metamizole. And, finally, the hourly water 
load to ensure hourly urine samples should be reduced, as it caused highly diluted urine 
samples, complicating quantification of sodium concentrations. This would also reduce the 
“water   load   effect”,   which increased GFR on the study days and masked potential drug 
effects on GFR. The high water load also caused many urinary 6-keto-PGF1α concentrations 
below the lower limit of quantification (LLOQ). In the literature, different methods of 
handling values below the LLOQ are described [115, 116], but every method has its 
limitations. In a first approach, we decided to set all values which were below the LLOQ to 
LLOQ, thereby overestimating the true concentrations. Since we did not observe a decrease 
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for the urinary sodium excretion, the sodium concentrations have to be determined using a 
more sensitive method to be able to see whether the effects of metamizole on sodium 
excretion really are different compared to Naproxen. Regarding the urinary 6-keto-PGF1α 
excretion, we were able to see the inhibition under naproxen since the collected baseline 
samples were quantifiable and the following samples under treatment fell under the LLOQ, 
an effect which was not caused by increased urine dilution. Therefore, we were able to show 
the inhibition, but we were not able to exactly quantify the extent of the inhibition.  
In general, the question remains whether differences in the effect on renal function 
between metamizole and a conventional NSAID can really be demonstrated in healthy salt-
depleted volunteers with a low sodium diet as the only stressor. [117] This also leads to the 
question whether it would be more promising to expose more susceptible individuals such 
as e.g. patients with liver cirrhosis [109], which on the other hand may raise ethical 
concerns. 
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4.2. Conclusions 
From the results of our studies, we can conclude that: 
- Metamizole-induced agranulocytosis remains a severe adverse drug reaction despite 
therapeutic options. 
- Female sex, triple blood cell line dyscrasia, older age, and concomitant treatment 
with methotrexate were identified as risk factors for a fatal outcome. 
- The minimal incidence rate of metamizole-induced agranulocytosis seems to be 
between 0.46-1.63 per million person-days. 
- A large proportion of cases (around 50%) occurred during the first 7 days of 
metamizole treatment. 
- A history of allergy, previous leucopenic episodes, infection with hepatitis C and 
concomitant use of cytostatic agents (including at immunosuppressive doses) might 
be risk factors for metamizole-induced leucopenia and require further study. 
- Metamizole inhibits renal excretion of the prostacyclin metabolite 6-keto-PGF1α 
similar to naproxen, suggesting that metamizole inhibits renal prostaglandin 
synthesis. 
- Despite inhibition of renal 6-keto-PGF1α excretion, metamizole had no significant 
effect on inulin clearance or renal sodium excretion in healthy, sodium-depleted 
subjects, whereas naproxen showed a trend to decreased sodium excretion. 
- Further studies in more susceptible individuals, looking also at renal plasma flow 
have to be conducted to evaluate differences in the effects on renal function 
between metamizole and NSAIDs that would explain the better renal tolerability of 
metamizole observed in the clinical setting. 
In general, metamizole should always be prescribed on a case by case basis balancing the 
risk for myelotoxicity against the ADR profiles of alternative analgesic agents. 
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4.3. Outlook 
The characterization of cases and the search for risk factors is limited by the nature of 
the feasible study designs. Of course, our identified possible risk factors need further 
confirmation in a larger case collective. Since the identification of patients at risk of 
developing this adverse reaction prior to exposure is crucial, a known genetic predisposition 
would be a fundamental step in the safe use of this compound. This would allow to prevent 
exposure of at-risk patients, therefore avoiding morbidity and mortality, and saving 
expenses for the treatment without losing the drug due to withdrawal from the market. For 
clozapine-induced agranulocytosis, several reports indicate that specific HLA variants may be 
associated with this adverse event [118-120]. For metamizole-induced agranulocytosis, data 
from current genomic technologies are lacking. Therefore, a genetic association study to 
identify involved pathways and potential predictive markers (such as HLA-types) in an 
appropriate number of cases and controls should be the next step.  
Concurrently, the uncovering of the mechanism behind the toxicity including the 
resolution of the question whether a metabolic toxicity on granulocyte progenitors and/or 
an immune-mediated toxicity cause this adverse reaction would facilitate the understanding 
of this adverse drug reaction. The knowledge of the mechanism of toxicity may help to 
understand risk factors and perhaps also offers therapeutic options and/or prevention 
possibilities and may be of importance regarding the development of new, safer, 
compounds. 
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